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CHAPTER I 
INTRODUCTION AND OBJECTIVES OF THE STUDY 
9 

Flow cytometry is a new technology which allows rapid quantitative evalua-
tion of cell numbers, cell properties or cell constituents by electrical or 
optical signals, which are generated and sensed while cells in an aqueous sus-
pension pass a sensing region. 
Flow cytometry started in 1956 with the development of a cell counting in-
strument by Coulter (1). In 1956 Kamentsky et al (1) introduced an improved 
flow system which enabled the simultaneous analysis of electrical and opti-
cal signals, van Dilla et al (3) and Göhde et al (4) independently developed 
flow systems using various flow chambers and improved optical and elec-
tronical devices. Later on Fulwyler adapted a flow system with droplet gene-
ration and a deflection method as introduced by Sweet (5,6) to permit cell 
sorting. Bonner et al (7) introduced a sensor which enabled cell sorting based 
on fluorescence. In the last ten years interest in flow cytometry has gradu-
ally increased,which is reflected in further instrumentational development 
and a growing number of biomedical applications. The developments and achie-
vements in flow cytometry are collected in the proceedings of the four inter-
national symposia on flow cytometry (8,9,10,11) and recently reviewed exten-
sively by Melamed and Mullaney (12). 
Flow cytometry was introduced in clinical research by Göhde, Schumann, 
Büchner, Andreeff and Barlogie in Germany, by Haanen, Wessels and Hillen in 
the Netherlands and by Darzynkiewicz and Kamentsky in the U.S.A. (13). 
Initially, flow cytometry was limited to the measurement of the relative DNA-
content of individual cells (DNA-flow cytometry); a preference which is under-
standable by the fundamental importance of DNA and by the availability of 
reproducible DNA-stai ning methods. DNA-flow cytometry was mainly employed to 
cytokinetic studies in various tumors, and its potential for widespread 
application was supposed to exist especially in the field of cancer research 
and medical oncology (13,14). 
The clinical application of DNA-flow cytometry in Nijmegen started in 1972 
and was applied to the study of proliferation kinetics in patients with acute 
leukemia. The effort to apply DNA-flow cytometry to leukemia was inspired by 
3 
new knowledge about cell kinetics in leukemia obtained by Η-thymidine auto­
radiography (15). With this technique it was found that leukemic blast cells 
have a varying, but generally prolonged generation time (16,17,18,19,20). 
The disappointing results in the chemotherapeutic treatment of acute leukemia 
were attributed to the presence of a large number of slowly proliferating or 
resting cells,which are difficult to eradicate with cytostatic drugs. However, 
11 
it was expected that, with properly timed drug scheduling causing cellrecruit-
ment or cellsynchronization, the cytotoxic effects were to be enhanced (21,22). 
3 
For this reason cellkinetic monitoring became essential, for which H-thymi-
dine autoradiography was unpractical because this method is too laborious and 
time consuming. Lonsequently, DNA-flow cytometry as a rapid and reliable me­
thod for cell cycle analysis was considered to be the obvious way. 
The results of cell kinetic studies in acute leukemia performed with DNA-
flow cytometry by hillen et al (23) were consistent with previous studies, 
3 
accomplished with Η-thymidine autoradiography. Moreover Hillen et al were the 
first to demonstrate with DNA-flow cytometry the cytokinetic effects on leu­
kemic cells of prednisone, cytosine arabinoside, adriamycine and vincristine 
(24). They demonstrated also the prognostic potential of the pretreatment 
S-phase compartment in patients with acute myeloblastic leukemia to attain 
complete remission (25). However, dispite these encouraging results, clinical 
application of DNA-flow cytometry was hampered by the inadequacy of one-para­
meter measurements,which will make no distinction between various cell types 
or maturation levels in heterogeneous bone marrow samples. Moreover, one 
became aware of a source of error caused by contamination of bone marrow as­
pirates with nucleated cells from the circulating blood. 
The objective of this thesis was to extend the applicability of flow cyto­
metry in clinical hematology by 
1) determination of the clinical significance of DNA-content analysis in leu­
kemic bone marrow, 
2) by addressing the problems connected with the heterogeneity of cells in 
bone marrow and blood samples. 
Basicly, this problem was approached in three ways: 
a) by the development of a procedure to quantify the amount of peripheral 
nucleated cells in bone marrow aspirates, 
b) by the application of counterflow centrifugation (elutriation) to attain 
enrichment of cell classes, prior to flow cytometric analysis, 
c) by the application of multiparameter flow cytometry to analyze cells 
simultaneously on different biological properties to enable discrimination 
between various cell classes. 
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CHAPTER II 
THE CELL CYCLE AND KINETICS OF HEMATOPOIESIS 
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THE CELL CYCLE PHASES 
During the interval between two successive mitoses (called the interphase), 
a series of cell metabolic states can be distinguished which represent various 
phases of the cell cycle (1,2,3). 
After mitosis it takes some time before DNA-replicati on starts. This gap-
period is called the G .-phase. The period during which the genetic material 
deoxyribonucleic acid (DNA) is replicated is called the S-phase. This period 
is followed by a premitotic resting or gap period, the Gp-phase. The G?-phase 
ends at mitosis, the M-phase (figure 1). It has been recognized that during 
the G,-phase, RNA-synthesis increases before DNA replication starts. Based on 
differences in RNA content therefore, early G,-celis can be distinguished from 
late G1 cells (4,5). 
It appears that the S-phase in most mammalian cells takes about 6-8 hours. 
The duration of the G?-phase is about 1-2 hours, whereas mitosis takes place 
in 30-70 minutes. The G^-phase is the most variable period of the cell cycle 
Self maintaining 
Cycling pool stem cell pool 
Figure 1. Cell populations and the phases of the cell eyole. 
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and may vary from a few hours to several months depending on the type of animal 
or tissue from which the cell originates. 
KINETICS OF HEMATOPOIESIS 
With regard to its kinetics, bone marrow consists of a mixture of three 
different cell populations (1,2,3). The first cell population consists of 
cycling cells; i.e. cells that are continuously dividing and traversing the 
cell cycle (progenitor cells). The second cell population contains cells that 
leave the cell cycle after a certain number of divisions, in order to diffe­
rentiate and to die (myeloid, erythroid and lymphoid cells). The third cell 
population contains cells that leave the cell cycle temporarily and remain 
in a dormant state until environmental conditions stimulate their reentry 
into the cell cycle (hematopoietic stem cells). The dormant state of these 
cells is commonly designated as the G0-phase of the cell cycle (figure 1). 
Hematopoietic tissue is one of the most rapidly proliferating cell com­
partments in the body and consists mainly of proliferating cells that are 
differentiating to permanent non-dividing cells. The selfmaintaining capacity 
of the hematopoietic system is confined to a morphological unrecognizable 
population of stem cells and progenitor cells (less than 0.1 t of bone marrow 
cells). 
Like all tissues, the generative activity of bone marrow depends on the 
cell cycle time (the time interval between two successive mitoses), the frac­
tion of cycling cells (the growth fraction) and the rate of cell loss (the 
fraction of cells that die or migrate to other tissues). The number of cells 
produced per unit of time depends on the cell cycle time and the growthfrac-
tion, whereas the rate of cell loss determines the number of cells that 
leaves or die per unit of time. In normal steady state conditions the number 
of cells produced per unit of time is equal to the number that is lost. 
CELL CYCLE ANALYSIS 
3 
The fraction of cells in S-phase can be determined with Η-thymidine auto-
3 
radiography, Η-thymidine uptake or with flow cytometry (1,6). 
3 
Η-thymidine is incorporated into DNA during the S-phase. The percentage 
of cells taking up the label after a given exposure can be determined by auto­
radiography and expressed as the labeling index (LI) which corresponds with 
20 
with the percentage of cells in S-phase. 
3 
After flash labeling with H-thymidine the cohort of cells in S-phase which 
is labeled, may be followed as it enters mitosis and the time course of labeled 
mitosis can subsequently be recorded. Theoretically such percent labeled 
mitosis curves (PLM-curves) permit measurement of the time durations of the 
various cell-cycle phases. However, in actual practice, biological variation 
damp these PLM-curves and render such measurements less precise. 
The continuous labeling method permits determination of the growth-frac­
tion, whereas duration of the cell-cycle and the S-phase can also be deter­
mined by this method. 
3 
The number of cell divisions as a function of time after application of H-
thymidine can be derived from the decreases of the mean grain grount, whereas 
under certain conditions, the mean grain number per nucleus gives information 
of the DNA-synthesis rate per cell. 
Double labeling provides another method to estimate the duration of the 
3 14 
S-phase. In this method two isotopie labels, e.g. Η-thymidine and C-thymi-
dine are injected with a known short interval of about 1-2 hours. Cells 
14 3 
labeled with С alone can be distinguished from those labeled with H, and 
allow the computation of S-phase and cell-cycle duration. 
3 
Η-thymidine autoradiography has been applied succesfully in numerous 
cellkinetic studies and has added greatly to the knowledge of cell growth. 
However, autoradiographic methods are time-consuming and their applicability 
to studies in vivo is limited. 
Automated methods for studying cell kinetics, which are less time-consuming, 
3 
have become available. The uptake of Η-thymidine may be assessed rapidly by 
scintillation counting, measuring the désintégrations per minute of incorpo-
rated labeled thymidine. 
Unfortunately thymidine availability and uptake show marked variations in 
individual cells so that comparison of total scintillator counts may not re-
flect the proliferative rate. 
A new technology concerns DNA-flow cytometry of which the application in 
clinical hematology forms the subject of this thesis. As indicated in chapter 
I, DNA-flow cytometry is an objective, reliable and rapid method to 
determine the relative number of cells in the various cell-cycle 
phases. However, up to now estimation of absolute phase durations or growth 
fraction was not possible with this method, whereas the heterogeneity of the 
cell-suspensions has limited its clinical application thus far. 
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CELL-KINETIC DATA OF NORMAL BONE MARROW IN MAN 
Estimates of the labeling index (LI) for granulocyte precursors have 
ranged from 30-75 % (mean 43 %) for myeloblasts, and about 20 % for myelocytes, 
implying a rapid rate of myeloid cell proliferation (7,8). Cell cycle time and 
phase duration for granulocyte precursors are poorly defined. An estimate of 
S-phase duration by double labeling gave a value of 5-6 hours (9), but this 
is probably an underestimate, due to artifacts in the method. Percent labeled 
mitosis (PLM-) curves have been derived for granulocyte precursors in only 
two patients with normal bone marrow (10). Computed estimates of median values 
give a S-phase duration of about 12-13 hours and a cell-cycle time of 16-25 
hours. However, the shape of the PLM-curves did not allow accurate measure-
ments of the S-phase duration. 
Erythroid precursors also have a rapid rate of proliferation. Estimates 
of the LI range from 30-75 % with higher values for earlier cells in the 
maturation sequence (11,12,13). The S-phase duration is about 13 hours while 
the median values for the cell-cycle time are in the range of 16-26 hours 
(10). 
Little is known of the kinetics of other precursor cells in human bone marrow 
such as these from monocytes, lymphocytes, plasma cells and megakaryocytes. 
CELL-KINETIC DATA OF BONE MARROW IN PATIENTS WITH ACUTE LEUKEMIA 
The mean LI of myeloblasts in patients with acute myelogenous leukemia 
ranges in the bone marrow from 5 to 11 %, and in the blood from 3 to 9 % 
(8,14,15,16). Similar values are obtained for lymphoblasts in bone marrow 
and blood in patients with acute lymphoblastic leukemia (17). Mean values 
of S-phase duration and cell-cycle durations for leukemic blast cells are 
about 20 to 60 hours respectively and are longer than the estimates for gra-
nulocyte and erythroid precursors in normal bone marrow. 
Accumulation of cells in leukemia is supposed not to be caused by increa-
sed proliferation, but by a maturation block leading to a decreased rate of 
cell death and a delayed removal from the hematopoietic compartment. 
22 
REFERENCES 
1. Baserga R. 
The cell cycle and cancer. 
Marcel Dekker Inc. New York, 1971. 
2. Baserga R. 
The cell cycle. 
N. Engl. J. Med. 204, 453, 1981. 
3. Baserga R. 
Multiplication and division in mammalian cells. 
Marcel Dekker Inc. New York, 1976. 
4. Darzynkiewicz Z, Evenson DP, Staiano-Coico L, Sharpless TK, Melamed ML. 
Correlation between cell cycle duration and RNA-content. 
J. Cell. Physiol. 100, 425, 1979. 
5. Darzynkiewicz Z, Sharpless T, Staiano-Coico L, Melamed MR. 
Subcompartments of the G-t-phase of the cell cycle detected by flow cyto-
metry. 
Proc. Natl. Acad. Sci. USA, 77, 6696, 1980. 
6. Aherne WA, Camplejohn RS, Wright NA. 
An introduction to cell population kinetics. 
Edw. Arnold Ltd. London, 1977. 
7. Wickramasinghe SN. 
Human bone marrow. 
Blackwell Scientific Publications, 1975. 
8. Tannock I. 
Cell kinetics and chemotherapy: a critical review. 
Cancer Treat. Rep. 62, 1117, 1978. 
9. Lala PK, Maloney MA, Patt HM. 
Measurement of DNA-synthesis time in myeloid-erythroid precursors. 
Exp. Cell. Res. 28, 628, 1965. 
10. Strijckmans P, Cronkite EP, Fache J. 
Deoxyribonucleic acid synthesis of erythropoietic and granulopoietic cells 
in human beings. 
Nature 211, 717, 1966. 
23 
11. Kesse-Elias, Harriss EB, Gyftani E. 
In vitro study of DNA-synthesis time and cell-cycle time in erythrocyte 
3 4 precursors of normal and thalassaemic subjects using H- and C-thymidine 
double labeling technique. 
Acta Haematol. (Basel) 38, 170, 1967. 
12. Lundmark KM. 
Bone marrow cell proliferation in health and in hematological disease 
during childhood. 
Acta Paediatr. Scand. (Suppl) 162, 1, 1966. 
13. Huber C, Huber H, Schmalzl. 
Decreased proliferative activity of erythroblasts in granulocytic stem 
cell leukemia. 
Nature 229, 113, 1971. 
14. Killmann SA. 
The kinetics of leukemic blast cells in man. 
Ser. Haematol, i, 38, 1968. 
15. Clarkson BD. 
Review of recent studies of cellular proliferation in acute leukemia. 
NCI. Monograph. 30, 81, 1969. 
16. Killmann SA. 
Kinetics of leukemic blast cel ls in man. 
C l i n . Haemat. 1, 1, 1972. 
17. Killmann SA. 
P r o l i f e r a t i v e a c t i v i t y of blast cel ls in leukemia and myelofibrosis. 
Morphological differences between p r o l i f e r a t i n g and non-prol i ferat ing 
blast c e l l s . 
Acta Med. Scand. 178
л
 263, 1965. 
24 
CHAPTER III 
PRINCIPLES OF FLOW CYTOMETRY 
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THE INSTRUMENT 
DNA-flow cytometry was performed with the Impulscytophotometer, ICP-11 
(Phywe, Göttingen, West-Germany). Two parameter flow cytometry was accom-
plished with an ICP-U, modified for two color analysis. 
The ICP-11 consists of a detector unit and electronic components (figure 
1). The detector unit accomodates an illuminating system, including a high-
pressure mercury lamp, a measuring chamber, a photomultiplier tube with pre-
amplifier, and a pump to drive the cell suspension and the rinsing fluid. 
The electronic components consist of power supplies, a multichannel analyzer 
with display facilities, an X-Y recorder and an oscilloscope adapted with 
a data storage paper-tape punch unit. 
The actual measuring procedure is as follows: the stained cell suspension 
is sucked through a (100 μη wide) capillary. The exit of this capillary, con­
stituting the measuring field of the instrument, is adjusted to the focal 
BLOCK DIAGRAM ICP-11 
DETECTOR SYSTEM 
obser-
vation 
ocular 
obser­
vation 
f i l ter 
t i l t i n g 
m i r r o r • 
b arr ier 
f i l ter 
· * • 
HV 
supply 
J 
photo 
multiplier •ñ 
lamp 
HBO 100 excitation (¡ i ters 
beam 
spit t t ing 
H 
check 
valve 
stabifized ' 
И flow 
chamber 
vacuum 
pump 
ELECTRONIC SYSTEM 
cathode 
ray 
cathode 
ray 
tube 2 
peak 
detector 
multi 
channel 
analyzer 
pulse rate 
meter 
supply 
rinsing 
fluid 
sample 
suspen­
sion 
T Z paper 
tape 
punch unit 
PDP 11/45 
computer 
Figure 1, Block diagram of ICP-U 
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plane of an objective. The measuring field is homogeneously illuminated 
(Köhlers' principle) by incident excitation light. The wave length of the 
excitation light can be adapted to particular fluorochromes by different ex-
citation filters (figure 2). Every stained cell passing the measuring field, 
emits a fluorescent light-pulse. The height of each pulse is proportional to 
the amount of the dye present, which reflects the quantity of the substance 
to be measured. The emission light passes a dichroic mirror and is reflec-
ted to a photomulti plier or to an observation device. The fluorescent light 
is converted by the photomultipiier to an electrical signal, which is propor-
tional to the intensity of the optical pulse. Interference filters in front 
of the photomultiplier are adaptable to desired optimal wave length. The 
electric signals are analyzed for amplitude and stored in a multichannel 
pulse-height analyzer. The analyzer delivers a frequency-distribution of the 
fluorescent light-emission per cell in the measured cell suspension. The 
results of a measurement are automatically recorded in a histogram and are 
typed out by a paper-tape punch unit. The histogram is read out and analyzed 
by a PDP 11/45 computer. Hard copies are provided by a Gould 5005 unit. 
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Figure 2. Sahematic drawing of the optical arrangement of the ICF-ll 
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Figure 3. Sohematia drawing of the optical arrangement of the ICP-11 modified 
for two color analysis. 
In the ICP-11 modified for two parameter analysis a second photomult ipl ier 
is ins ta l led ( f igure 3). By combination of speci f ic dichroic mirrors and 
interference f i l t e r s one of the photomultipliers converts for example green 
l i g h t , and the addit ional photomult ipl ier red l i g h t . After d ig i ta l conversion, 
signals are stored in a multichannel analyzer (Nuclear Data-100) according 
to the i r re la t ive magnitude. The di g i t a l i zed signals are stored on a magnetic 
tape and processed through a PDP 11/45 computer. Hard copies of the h is to-
grams are provided by a Gould 5005-unit. 
THE DNA-HISTOGRAM 
A DNA-histogram of an asynchronously growing cellpopulation is shown in 
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on tki j.hscir>c>a. 
figure 4. The large peak represents the G.,-phase cells, the smaller peak at 
twice this DNA-content the G« + M-phase cells and the continuum between these 
peaks reflects the S-phase cells. Although the DNA-content of normal diploid 
cells are found to be very constant the G, peak actually shows a variation 
of measured values around a mean. The extent of this variation is expressed 
as coefficient of variation (CV) and is mainly affected by the cytochemical 
and instrumental variability. 
DNA-histograms of bone marrow or blood samples show CVs' of the G, peak ran-
ging from 2.5 - 5.0 % (median: 3.2 %). Factors that affect measured DNA-
distributions in homogeneous cell populations are the growth fraction and 
the relative durations of the cell-cycle phases. Additional variations are 
introduced by the heterogeneity of the cell populations. 
The percentages of cells in the various phases of the cell cycle can be 
calculated from DNA-histograms by different mathematical techniques, in this 
thesis the planimetrie method described by Baisch and Göhde was used (1). 
With this method the percentage of S-phase cells is calculated from the dis-
tance on the abscissa between the middle of the G.,-peak and the G;, + M-
peak, multipli-ed by the height of the curve at half distance between the G, 
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Figure 6. Two techniques for the analysis of DNA-distributions. 
a. A planimetrical method in which a rectangular box is used to 
approximate the S-phase population. 
b. A graphical method in which the left half of the G.. peak and 
the right half of the G? + M peak are used to estimate the G^ 
and G9 + M-phase fractions. 
and the G2 + M-peak (Figure 5a). This sample estimation of the S-phase com-
partment, in general arrives at the same results as obtained by sophisticated 
computerized analysis of histograms. However, this planimetrie method is not 
applicable to histograms of synchronous growing cell populations. Histograms 
from synchronous growing cell populations were analyzed according to a method 
described by Barlogie et al (2).. This method is based on the assumption that 
the left half of the G^-peak and right half of the G2 + M-peak represent only 
6,- or 6? + M-phase cells respectively, with no contribution of S-phase cells. 
The peak halves are folded around their respective modes, forming two symme-
tric peaks whose areas yield the fraction of cells in each of these two cell-
cycle phases. The S-fraction is then obtained by subtraction (Figure 5b). 
DISPLAY AND ANALYSIS OF TWO-PARAMETER MEASUREMENTS 
The simpliest way of displaying two-variable data, both electronically 
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and computationally is in a saatter-plot (3). Each cell in such a plot is re­
presented by a dot whose X and Y coordinates are proportional to the two cell 
characteristics. One disadvantage of scatter plots, however, is their limited 
dynamic range. Regions, where the frequency of cells is high may become com­
pletely black before a sufficient number of data-points are plotted to the 
low-frequency areas. 
A more quantitative method for the presentation of two-variable data is 
the perspective plot. The values of the two variables are presented as coor­
dinates on a horizontal plane; the frequency of objects appears as distance 
above this plane, so that the distribution appears as a solid figure e.g. 
as peaks and valleys. Figure 6 shows the perspective display (with hidden 
lines removed) of the propidium iodide (red) and FITC (green) fluorescence 
of a bone marrow sample. Although perspective displays present two variable 
data in an easily visualized form, they provide little quantitative topogra­
phic information. For example it is almost impossible to determine bivariate 
Figure в. A perspective plot of tuo variable data (e.g. DNA and protein con­
tent of individual cells). 
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modes or standard deviations from a perspective display. Density interval maps, 
which were used in this thesis, overcome this limitation. Figure 7 shows 
an example of such a plot, representing a two-dimensional array of grey levels, 
which correspond to equal steps (or intervals) in the logarithm of the cell 
numbers. 
The quantitative results of two parameter measurements are usually based 
on the information contained in subsets of cells selected by electronic gating. 
This information includes the distribution statistics of the cells within a 
certain window of which the position, the size and shape are defined (4). 
CELL-STAINING 
DNA-staining. For DNA-flow cytometry ce l ls were stained with ethidì urn-
bromide (EB). EB binds spec i f i ca l l y to nucleic acids,mainly by in terca la t ion 
in double-stranded DNA and RNA. This binding results in about 20-fold i n -
crease of the fluorescence quantum-efficiency of the dye. In consequence the 
I I I I I I I I I | M I M I I I I | I I I I I I I I I | I I I I I I I I 1 1 ' ' ' ' ι I I I I [ I I I I 1 1 I I I | I I I I 
DNA 
Figure 7. Density interval map of bjo variable data (e.g. DNA and protein 
content of individual sells). The tuo dimensional array of grey 
levels correspond to equal steps in the logarithm of the cell 
numbers. 
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intensity of fluorescence emission increases by a factor between 50-100 (5). 
The maximum excitation of EB is about 500 nm, and the maximum emission about 
600 nm (orange-red). 
In the studies of this thesis,cell staining for DNA was performed accor­
ding to the method of Krishan (6). In this method about 10 cells of blood 
or bone marrow sample are added to 5 ml hypotonic EB-solution containing 
0.1 % trisodium citrate and 25 mg/1 EB (pH 7 6). Cells are lysed in this 
solution and nuclear DNA is immediately stained with EB at room temperature, 
allowing flow cytometric analysis within few minutes Staining of nuclear 
RNA can be prevented by adding RNA'se (1 mg/ml) to the cell suspen­
sion. 
Бгг-Л апеоио зіагпггд for Dik avC H.A. Acridine Orange (A0) was used as 
metachromatic fluorochrome for simultaneous staining of DNA and RNA in 
unfixed bone marrow or cultured eel Is,according to the method described by 
Tráganos and Darzynkiewicz (9). Upon excitation with blue light, A0 inter-
calated into double strands nucleic acids (DNA, some RNA) fluoresces green 
(530 nm), while stacked on single stranded nucleic acids (RNA) it fluores-
ces red (640 nm). Since a large amount of RNA in situ is double stranded 
it must be selectively denaturated to the single stranded form prior to 
staining. This is accomplished by using EDTA as chelating agent. 
The unfixed cells are made permeable to A0 and chelating agents by short pre-
treatment (30 sec) with Triton X-100 at pH 1.0. The staining procedure ac-
tually is as follows: aliquots of 0 2 ml of cells suspended in PBS, contai-
ning 2 mM MgClp and 10 % fetal calf-serum are mixed with 0.4 ml of a solution 
containing 0.1 % (v/v) Tnton-X-100, 0.08 N HCl and 0.15 M NaCl. After 30 
sec 1.2 ml A0 (20 gg/ml) in 10"3M EDTA, 0.15 M NaCl, 0.1 M phosphate-citrate 
buffer (pH 6.0) is added, resulting in a final dye concentration of 3 0 χ 
_ Q 
10 M АО. Measurements are performed within 10 m m 
StTUL-taneow; statuirà foc СЛ/l and protevn. Double staining of cells for both 
DNA and protein can be accomplished by using the fluorescent dyes propidium 
iodide (PI) and fluorescein isothiocyanate (FITC), which have about similar 
excitation spectra but differing and separable emission spectra. PI inter­
calates into DNA and RNA analogous to EB. Since PI bound to DNA has an emis­
sion maximum near 615 nm, compared to 600 nm for EB, and FITC near 530 \M, 
spectral separation is obtained using the PI/FITC combination (8). Although 
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some overlapping of the two colors occurs, adequate resolution is obtained 
by using appropriate color filters (figure 3). 
The staining method as recently adjusted to hematopoietic cells by Criss-
man et al is described in chapter VIII (9). 
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R.S.G.Holdrinet, J.van Egmond, J.M.C.Kessels and C.Haanen 
Experimental Hematology, S, 103, 1980 
39 
ABSTRACT 
Peripheral blood admixture in bone marrow aspirates of twenty patients 
with hematological diseases were studied either with Cr-labeled autologous 
125 
erythrocytes or I-labeled albumin. 
In these bone marrow aspirates 97.0 + 4.2 % (mean + SD) of the hemoglobin 
content appeared to be derived from peripheral blood. Assuming the presence 
of a proportional number of peripheral nucleated cells, one may calculate 
therefore the fraction of peripheral nucleated cells in bone marrow aspirates 
(F . ) using the ratios of Hb-level and nucleated cell count in respectively 
blood- and bone marrow samples. The F . in the twenty patients studied, 
showed a considerable variation (6 - 93 7c). In a group of 25 healthy con-
trols the mean F , + SD was 14 + 8 %. 
pb -
From the present study it is evident that reliable results in quantitative 
bone marrow studies can only be obtained, if the fraction of peripheral nu-
cleated cells in bone marrow aspirates is considered. 
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INTRODUCTION 
Bone marrow aspirates are to a variable extent contaminated with periphe-
ral blood. Usually, bone marrow is aspirated to determine the presence or ab-
sence of disease and for this purpose peripheral blood contamination is gene-
rally not supposed to be a major problem. However, if bone marrow aspirates 
are used for quantitative measurements e.g. as in determining its prolifera-
tive activity or its ability to form colonies, peripheral blood contamination 
may have a considerable influence on the results. In studying bone marrow pro-
liferative activity in leukemias, we were also confronted with this problem. 
For this reason we determined the extent of peripheral blood admixture in 
bone marrow aspirates of 25 healthy controls and of 20 patients with various 
hematological diseases. 
Based on results of the present study, a method is introduced for the 
calculation of the fraction of peripheral nucleated cells in bone marrow as-
pirates (F p b). 
PATIENTS AND METHODS 
Twenty patients with hematological diseases (age 17-64 years) and twenty-
five healthy controls (age 22-34 years) were studied. Ten patients were in-
51 jected intravenously with 20 uCi Cr-labeled autologous erythrocytes whereas 
125 in ten additional patients 2 jCi I-labeled albumin was administered. Three 
51 hours after the injection of Cr-autologous red cells and ten minutes after 
125 
the I-albumin injection, a sternal and a venepuncture were performed al-
most simultaneously. 
Both bone marrow aspirates (0.5 - 1.0 ml) and venous blood samples were 
anticoagulated with 1.0 ml acid citrate dextrose (ACD, formula A). The weights 
(volumes) of the samples were measured on a microbalance and of all specimens 
the nucleated cell count and the hemoglobin level were determined. The radio-
activity of the specimens was measured with a gamma-scintillation counter 
(Baird Atomic). The total radioactivity in the bone marrow aspirate and the 
peripheral blood sample was related to the hemoglobin content of the samples 
(cpm/mg Hb). The values obtained in the bone marrow aspirate and the peri-
pheral blood sample, were compared to each other. 
The fraction of peripheral nucleated cells present in the bone marrow as-
pirate (Fu) was calculated according to the formula as described in RESULTS. 
The F u was determined also in twenty-five additional healthy controls. 
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Patient 
1 
г 
3 
4 
5 
6 
7 
8 
9 
10 
Done 
CPV," 
132 5 
138 9 
180 3 
146 3 
103 4 
114 3 
129 1 
108 e 
158 7 
39 1 
rar>-ow 
Herpo-
globiη 
content 
(mg) + 
96 9 
168 1 
107 2 
142,3 
70 0 
93.9 
132 2 
58 1 
89 0 
39 6 
Per onera 
CPV ' 
128 5 
240 4 
96 1 
110 4 
159 4 
90 0 
95 9 
137 5 
149 0 
123 9 
M 
blood 
Heno-
globin 
content 
i-»g> 
91.9 
293 5 
50 9 
102 2 
100 1 
75 7 
92 9 
71 3 
82 7 
127 0 
ean + SD = 
СРЧ/rg Hb ir 
LPM/mg Hb in 
к 100 -
98 
101 
89 
95 
93 
102 
95 
97 
99 
101 
= 97.0 + 4.1 ï 
зм* 
Pb 
ц 7 
Table 1. Fcrirheral blood in Ъокс narrcv азрігаіез measured with С 
labeled autologous aryikrocyte^. 
Patient 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Bone 
CPM» 
112 7 
150 8 
116 1 
100 1 
84 4 
87 5 
66 1 
111 5 
93.8 
52 7 
narrow 
hemo­
globin 
content 
¡ng)-
63 1 
146 3 
67 9 
63 7 
68 6 
38 2 
72 0 
44.2 
48 4 
50 7 
Periph 
CPM' 
.04 7 
128 3 
118 0 
111 8 
90 7 
113 7 
75 4 
124 4 
110 9 
53 8 
eral blood 
Hemo-
globi η 
content 
(mg) 
52 0 
122 1 
64 9 
69 2 
72 4 
49 0 
77 6 
47 2 
57 6 
54 3 
Mean t SO = 
C'M'Tig )>) "i 
CP'i/ng hb in 
χ 100 • 
89 
98 
94 
97 
98 
99 
94 
96 
101 
105 
:97 1 * 4 3 % 
Bv* 
Pb 
* CPM = counts per minute in total bone -narrow aspirate or blood sample 
t Hemoglobin content = hemoglobin (mg/dl ) χ volume (ml) 
X BM = bone marrow, Pb = peripheral blood 
Table 2. Ferirhcral blood in hone та роьэ aspirateJ measured vith 
labeled atbumin. 
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RESULTS 
y.cac.ivem^ìit rf гсгірпе^лі Hood in lor.c rnarvo-j ajbi-rutcu. 
If a bone marrow sample contains non-circulating hemoglobin belonging to 
the marrow compartment, one would expect the radio-activity per mg Hb in the 
bone marrow aspirate to be less than in the peripheral blood. 
51 Table I summarizes the results from patients injected with Cr-labeled 
autologous erythrocytes. The radioactivity per mg Hb in the aspirates was 
97.0 % + 4.1 % (mean + SD) of the radioactivity per mg Hb in the peripheral 
~ 125 
blood. In patients injected with I-labeled albumin similar findings were 
obtained: 97.1 % + 4.3 % (mean + SD) of the radioactivity per mg Hb in the 
peripheral blood was present in the aspirates (Table 2). 
We may conclude therefore that almost all hemoglobin in bone marrow aspi­
rates is in due fact derived from peripheral blood. 
Caloulation of the peripheral nualeated oeil fraction in bono marrou aspira­
tes. 
In a bone marrow aspirate the number of nucleated cells derived from peri­
pheral blood apparently is proportional to the amount of peripheral hemoglo­
bin present in the sample. As shown, nearly all hemoglobin in a bone marrow 
aspirate is derived from circulating blood. Consequently, neglecting a small 
error, the fraction of peripheral nucleated cells in a bone marrow sample 
(F . ) may be calculated from the nucleated cell count and the Hb level in 
both blood sample and bone marrow aspirate. 
In formula: 
HB.
 m
/Hb
n
, X NC. F . = bm pb pb_
 χ 1 0 0 % 
P b 
where pb = peripheral blood, bm = bone marrow and NC = nucleated cell count/ml 
The F , in the twenty patients is shown in Table 3. In these cases the 
^pb r a n 9 e s f r o m 6 " t 0 9 3 «· In s o m e cases findings were rather surori-
sing as almost all nucleated cells actually proved to be derived from peri­
pheral blood, although the aspirates were considered cell rich (case 8, 18 
and 20). On the other hand in a cell poor bone marrow aspirate (case 14) 69 % 
of the cells were derived from the bone marrow compartment. 
The F , in the twenty-five healthy controls was less divergent (Table 4). 
The mean F . was 14 t + 8 % (range 3 % - 37 %). 
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Nucleated cel 1 count 
к 106/g Hb 
Patient Diagnosis 
Periph­
er»! 
blood 
71 
472 
106 
104 
53 
80 
43 
1019 
ISO 
35 
109 
61 
55 
12 
43 
53 
51 
361 
71 
4020 
Bone 
marrow 
237 
8Θ8 
801 
497 
430 
142 
237 
1497 
1460 
142 
401 
1092 
191 
39 
91 
335 
309 
460 
115 
4304 
*> (*> 
30 
53 
13 
21 
12 
56 
18 
68 
10 
25 
27 
6 
29 
31 
47 
16 
17 
78 
62 
93 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Lymphoma 
AML 
Myeloma 
Vaquez 
Hodgkin 
Myeloma 
Anemia 
CLL 
ALL 
Lymphoma 
Myeloma 
A n e m a 
Myeloma 
AEL 
ALL (Remission) 
AML 
Hodgkiη 
CLL 
ALL (Remission) 
CML. 
AML = Acute Myeloblastic Leukenia 
ALL = Acute Lymphoblastic Leu kern a 
AEL = Acute Erythroblastic Leukemia 
CLL = C h r o m e Lymphocytic Leukemia 
CML = C h r o m e Myeloid Leukemia 
Table 3. The calculated fraction of peripheral nucleated cells in bone marrow 
aspirates (F .) of 20 hematological patients, 
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10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
Nuclea 
χ 
P e n pheral 
blood 
30 
43 
31 
38 
44 
45 
30 
37 
76 
32 
18 
68 
32 
36 
38 
44 
29 
36 
44 
36 
50 
32 
31 
42 
31 
ted cell 
106/g Hb 
count 
Bone marrow 
584 
360 
509 
180 
118 
373 
994 
261 
317 
248 
304 
310 
211 
522 
348 
261 
721 
242 
199 
360 
497 
186 
118 
379 
242 
Mean + 5D 
F
ob (*) 
5 
12 
6 
21 
37 
12 
3 
14 
24 
13 
6 
22 
15 
7 
11 
17 
4 
15 
22 
10 
10 
17 
26 
11 
13 
14 + 1 
Table 4. The aalaulated fraction of peripheral nualeated cells in bone marrow 
aspirates (F ,) of 25 healthy controls. 
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DISCUSSION 
It is known that red blood cells leave the bone marrow compartment as reti-
culocytes (1). The hemoglobin present in the bone marrow compartment therefore 
is derived mainly from erythroblasts and young reticulocytes. The reticulocyte 
number of the bone marrow compartment is estimated to be of the same order of 
magnitude as the total amount of erythroblasts (2,3). Consequently, one may 
expect the amount of hemoglobin derived from the bone marrow compartment to 
be small compared to the total hemoglobin content in an aspirate. 
It has already been established by radioactive labeling studies in animals 
that mature erythrocytes in bone marrow samples represent circulating blood 
(4). Also in human beings it was already shown that bone marrow aspirates 
may be contaminated with peripheral blood to a large extent (5), while the 
influence on quantitative bone marrow studies of this artifact has been de-
monstrated as well (6,7). However, hitherto no practical method has been pro-
posed to quantify the fraction of perioheral nucleated cells in bone marrow 
aspirates. 
As demonstrated in the present study the amount of peripheral blood in 
a bone marrow aspirate is indicated by its hemoglobin content. Hence, one 
may calculate the peripheral nucleated cell fraction from the ratios of the 
Hb-level and nucleated cell count in both bone marrow aspirate and a simul-
taneously obtained peripheral blood sample. As shown, the fraction of peri-
pheral nucleated cells in bone marrow aspirates may be considerable especi-
ally in hematological diseases.Consequently, the relevance of considering 
this possible artifact in quantitative bone marrow studies is evident. 
For example, in measuring the proliferative activity in bone marrow aspirates 
of patients with leukemia (using autoradiography or DNA-flow cytometry), 
peripheral blood contamination may cause a fall in the proliferative cell 
fraction, as circulating blasts usually are less proliferative cells. The 
significance of this consideration is apparent as the proliferative activity 
in bone marrow aspirates is used as a kinetic rational in the chemotherapeutic 
treatment of leukemia (8).Moreover,several authors have stressed its prognos-
tic significance in predicting the likelihood of attaining remission, remis-
sion duration or survival time (9,10). The same reasoning can be applied 
for example to studies on the colony forming capacity of human bone marrow, 
as peripheral blood usually contains only a few colony forming cells. 
Application of the proposed correction method to studies in which bone 
marrow aspirates are used to quantify some bone marrow cell characteristics, 
46 
will contribute to an enhanced reliability of the obtained data. 
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ABSTRACT 
Flow cytometric analysis of bone marrow aspirates and blood samples were 
performed in 106 adult patients with acute leukemia in order to assess the 
size and the prognostic significance of the percentage of S-phase cells in 
the bone marrow (% S. ). A correction procedure was applied for the fraction 
of contaminating peripheral nucleated cells in bone marrow aspirates {% F . ). 
In 82 out of the 106 patients studied the % S. could be reliably determined 
and was compared to the % S. in 25 healthy controls. The % S. in these 
healthy controls ranged from 8.4 - 14.6 %. 
The median % S, in 31 patients with acute non-lymphocytic leukemia (ANLL) 
at diagnosis (11.3 %) and in 14 patients with ANLL at relapse (11.8 %) did 
not differ significantly from the median % S. in normal bone marrow (11.7 %). 
On the other hand in 12 out of 23 patients with acute lymphocytic leukemia 
(ALL) at diagnosis and in 6 out of 11 patients with ALL at relapse the % S, , 
ranging from 17.8 - 44.0 %, was much increased compared to normal. 
The prognosis,with regard to remission duration and survival of patients 
with ALL having a high % S. (> 15 %) was significantly worse than those with 
normal or low % S. (< 15 %). 
Aneuploidy was noticed in 7.7 % of the patients with acute leukemia at 
diagnosis, the incidence being significantly higher especially in patients 
with ALL at relapse (42.1 %). 
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INTRODUCTION 
The size of the S-phase compartment in bone marrow,measured with either flow 
cytometry (FCM) or tritiated thymidine autoradiography in normals and patients 
with acute leukemia.shows a considerable individual variation (1,2). Recently 
it was shown that bone marrow aspirates in patients with leukemia may be ex-
pected to be contaminated to a large amount with peripheral nucleated cells 
(3). Since the percentage of cells in S-phase in blood may differ from that 
in bone marrow, it is reasonable to assume that variations in the S-phase com-
partment in patients with leukemia, as determined in bone marrow aspirates, 
may partly be explained by the large variation of peripheral blood contamina-
tion in bone marrow aspirates. 
In the present study we determined the S-phase compartment in blood and 
bone marrow of patients with acute leukemia, taking into account, and correc-
ting for the amount of peripheral nucleated cells in bone marrow aspirates. 
The S-phase compartments of bone marrow and blood of patients with acute leu-
kemia were compared with those from healthy controls, and the prognostic sig-
nificance evaluated with regard to remission rate, length of remission and 
survival. 
MATERIALS AND METHODS 
Patients 
Flow cytometric determination of DNA-content (DNA-FCM) was performed of 
bone marrow aspirates and blood samples from 106 patients with acute leukemia. 
Studied were 40 patients with acute non-lymphocytic leukemia (ANLL), 3 pa-
tients with acute erythroblastic leukemia (AEL) and 25 patients with acute 
lymphoblastic leukemia (ALL) at the onset of disease, whereas 19 patients with 
ANLL and 19 patients with ALL were evaluated at first relapse. The diagnoses 
were made according to the currently accepted FAB-criteria (3), and confirmed 
at the W.H.O. Reference Centre for Leukemias, Villejuif, France and by the 
Netherlands' Bone Marrow Committee, Rotterdam. 
Only patients with more than 70 % leukemic blast cells in bone marrow were 
evaluated.The ANLL patients were treated according to the LAM-5 protocol of 
the EORTC, consisting of vincristine, adriamycin and cytosine arabinoside as 
remission induction therapy. The ALL-patients were treated with prednisone, 
vincristine, adriamycin and asparaginase supplemented with intrathecal metho-
trexate. 
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Studied were also 25 healthy controls of whom the bone marrow aspirates were 
subjected to both DNA-FCM and tritiated thymidine autoradiography. 
Sample processing 
From sternum or posterior iliac crest 0.5 - 1.0 ml bone marrow material 
was aspirated and anticoagulated with 2 ml acid citrate dextrose (ACD formula 
A). A venous blood sample was taken from an antecubital vein. Of both bone 
marrow and blood samples the Hb content and the cellnumber were determined. 
Staining was performed by adding 10 nucleated cells of blood or bone marrow 
sample to 5 ml hypotonic ethidium bromide solution (0.1 % trisodium citrate, 
25 mg/1 ethidium bromide) according to the method of Krishan (4). 
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The relative fluorescence of about 10 cells was measured in a ICP-11 pulse 
cytophotometer (Phywé Company, Germany). Distributions of DNA-content were 
analyzed utilizing the method described by Baisch et al (5). The coefficient 
of variation for the G, compartment ranged from 2.2 - 5.3 % (median 3.2 %). 
Correction for peripheral blood contamination of bone marrow aspirates 
The fraction of peripheral nucleated cells present in bone marrow aspirates 
(F ,) was calculated as recently described (6,7). Briefly, this method is 
based on the observation that almost all hemoglobin in bone marrow aspirates 
is derived from peripheral blood. Therefore determination of hemoglobin con-
tent and the number of nucleated cells in blood and bone marrow samples 
enables the calculation of the fraction of nucleated cells in the aspirate 
originating from the peripheral blood, according to the formula: 
ρ
 =
 Pb
 χ
 asp 
p b
 "
 N C
a c n
 Hb. sp pb 
where NC . and NC stand for the nucleated cell count respectively in peri­
pheral blood and bone marrow aspirate and Hb , respectively Hb for hemoglo­
bin content in peripheral blood and aspirate. 
Consequently, the percentage of S-phase cells in the bone marrow compartment 
can be calculated from the findings in the blood sample and the bone marrow 
aspirate according to the formula: 
* S.cn - (Fnh x * S . ) 
ο, ς _ asp ^ pb pb; 
/o bbm 
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where % S, , % S and t S , stand for the percentage of S-phase cells in res­
pectively bone marrow compartment, bone marrow aspirate and peripheral blood. 
However, with increasing F , , calculation of % S. from % S, and % S . pro-
3
 pb bm asp pb r 
gressively becomes less reliable. Consequently, according to an error analysis 
(given in the Addendum) bone marrow aspirates with a F . of more than 40 % 
were rejected for calculation of the S-phase compartment. 
Tritiated Thymidine Autoradiography 
In addition to DNA-FCM,the bone marrow aspirates of 25 healthy controls 
3 
were studied with H-thymidine autoradiography. To 100 μΐ of the bone marrow 
3 
cell suspension, 0.5 uCi H-thymidine was added and incubated for 60 min at 
370C. Smears were prepared, air dried, fixed in methanol and stained with May-
Griinwald Giemsa. 
The slides were covered with polyvynilidenechloride to prevent chemography 
of the overlayered Illford L4 photographic emulsion (8). Autoradiographs were 
examined after exposure during 14 days at 4 С The percentage of labeled cells 
was determined by counting 2000 nucleated cells. Cells with more than 
4 grains were considered to be labeled. The Labeling Index (LI) of erythroid 
and myeloid cells were determined separately and corrected for peripheral nu­
cleated cell admixture, according to the formula 
LI-M 
asp 
LI-M, bm - i- (F p b χ % M p b ) 
where LI-M, and LI-M stand for the LI of myeloid cells respectively in 
bone marrow compartment and aspirate, and % M . stands for the percentage 
of granulocytes in blood as determined with the Hemalog-D (Technicon). 
The determination of the LI of the various subclasses within the myeloid 
cell series was omitted since an accurate distinction between myeloblasts, 
promyelocyte and myelocyte was not quite possible on the autoradiographs. 
Statistical methods 
Analysis for differences in S-phase compartments between various groups 
of patients was performed utilizing the Student's-t-test. Comparisons of dura­
tion of response and survival were made utilizing the Gehan modification of 
the Wilcoxon analysis (9). Survival curves were calculated by the life table 
technique according to Kaplan and Meier (10). 
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RESULTS 
The eontaminat-Lon of bone marrow aspirates with peripheral nucleated cells 
The fraction of peripheral nucleated cells in bone marrow aspirates (F .) 
of healthy controls and patients with acute leukemia show a considerable 
variation (Figure 1). In normals the F . ranged from 3-36 % (median 15 % ) , 
in patients with ANLL and AEL from 1-95 % (median 12 %) and in patients with 
ALL from 1-76 % (median 7 % ) . In 7 patients with ANLL and in 1 patient with 
ALL the F . of bone marrow aspirates repeatedly exceeded 40 % at several at-
tempts, as indicated, these cases were excluded from evaluation. 
The S-phase compartment in healthy controls 
Table 1 summarizes the data obtained in the study of S-phase compartments 
(X Sbm) in 25 normals. The mean labeling index (LI) of all bone marrow cells 
was 11.0 + 1.9 % (SD). The mean LI of the myeloid cells was 9.1 + ¿Λ % and 
the mean LI of the erythroid cells 27.1 + 4.8 %. The mean % S. determined 
— bm 
w i t h DNA/FCM was 11.3 + 1.5 % (range 8.4 - 14.6 %). 
"/oFpb 
lOO-i 
8 0 -
6 0 -
4 0 -
2 0 -
NORMALS ANLL ALL 
(n=25) (n=62) (n=44) 
Figure 1. The fraction of peripheral nucleated cells in bone marrow aspirates 
(7° FT) in healthy controls and patients with acute leukemia. 
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j t í 'МЛ 
DNA 
3H-chynndine Autoradiographv F 1 » w Cytometry 
Median 
Mean 
SD 
Range 
LI(%) 
Myeloid 
Cells 
9 2 
9 1 
2 1 
β 7-14 5 
LU*) 
Erythroid 
Cells 
27 0 
27 1 
4 S 
17 0-34 7 
LI(*) 
Total 
В M 
10 8 
11 0 
1 9 
6 5-13 9 
% S 
Total 
ΒΊ 
11 2 
11 3 
1 5 
8 4-14 6 
Í S 
P e n ph 
Blood 
2 0 
2 0 
0 5 
1 6-3 1 
Table 1. The S-phase compartment гп 25 healthy controls 
DNA-FCM of normal blood reveals the precense of a median percentage of 
"S-phase" cells of 2.0 % (mean 2.0 + 0.5 % ) . However, this percentage must be 
considered artefactual as it is partly caused by interference of the relative 
large amounts of erythrocytes in blood samples. Consequently S-phase cells 
were supposed to be present in peripheral blood only, when the % S . exceeded 
a minimum threshold of 3.0 %. 
The S-phase compartment in bone marrow (% S, ) in patients with acute leukemia 
Reliable calculation of the percentage of S-phase cells in bone marrow 
[% S ) was possible in 31 ANLL patients, 3 AEL patients and 23 ALL patients 
at diagnosis and in 14 ANLL patients and 11 ALL patients at relapse. 
The % S, in normals and patients with acute leukemia is shown in Figure 2. 
In ANLL patients the median % S. at diagnosis was 11.3 % (mean 11.2 + 3.2 % 
SD) which does not differ from the median % S. in the heterogeneous normal 
bone marrow (11.2 %), and which is slightly higher than the LI of normal mye­
loid cells (9.1 %). In ANLL patients at relapse the median % S b m (11.8 %) was 
not significantly different from the median % S, at diagnosis. 
In three patients with AEL the % S. was considerably higher (i.e. 24.5 %, 
28,5 % and 34,5 %) which corresponds with the high LI of erythroid cells in 
normal bone marrow (27.1 %). 
In patients with ALL at diagnosis and at relapse the % S. ranged from 
5.2 - 37.5 %, respectively from 7.1 - 44.5 %. In 12 out of 23 ALL patients at 
diagnosis and in 6 out of 11 patients at relapse the % S, was higher than 
normal (> 15.0 %). In 4 patients at diagnosis and in 1 patient at relapse the 
% S. was low (< 8.0 t ) . The median % S.
m
 at diagnosis was 17.6 % and at re­
lapse 23.8 %, which is not significantly different. 
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NORMALS ANLL 
(n=25) (n = 31) 
AEL ANLL ALL ALL 
RELAPSE RELAPSE 
(n=3) (n = 14) (n = 23) (Π--11) 
Figure 2. The percentage of 3- >Уаве cells in the bone marrow in norr.alr, and 
pavienis with acute leukernia at diagnosis and at relapse. 
Aneuploidy occurred in 3 patients with ANLL and 2 patients with ALL at 
diagnosis, and in 3 patients with ANLL and 8 patients with ALL at relapse. 
A l l patients with aneuploidy at the onset of disease showed the same DNA-
content abnormality at relapse. In 5 patients with ALL aneuploidy occurred 
only at relapse. 
The percentage of S-phase cells in peripheral blood in patients with acute 
leükerria (% S ,) 
pb 
In almost a l l patients the percentage of S-phase cel ls in peripheral 
blood {% S . ) was lower than in the bone marrow (% S. ) , as demonstrated in 
Figure 3. 
In ANLL patients at diagnosis a high % S . (> 3 %) was observed in 14 out 
of 35 patients (range 3.1 - 7.5 %) and in 2 out of 19 patients at relapse 
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Figure 3. The percentage of S-phase cells in peripheral blood (% S
 } ) oomparec 
to the percentage of S-phase cells in bone marroi) (% S, ) in pa­
tients with aoute leukemia. 
(3.4 % respectively 3.9 % ) . In 3 AEL patients the % S
 b was pronounced (14.2 %, 
17,2% respectively 22.6 %) corresponding with the presence of erythroid cells 
in peripheral blood. 
The * S . was more than 3 % in 12 out of 23 patients with ALL at diagnosis 
(range 3.1 - 24.3 %) and in 8 out of 11 patients at relapse (range 4.6 -
20.4 %}. 
In peripheral blood aneuploidy was noticed in all patients in which this 
abnormality could be demonstrated in the bone marrow aspirate. 
Relationship of % S. to age, initial white blood cell count, remission-rate 
and prognosis 
No correlation existed between either the % S b m and the initial white blood 
cell count in ANLL patients (r = 0.17) and ALL patients (r = 0.42) nor between 
age and % S. (r = 0.23 respectively 0.31). 
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ALL 
100 
5 0 
Α ( η - Ί 1 ) 
1 
B(n=12) 
A Sbm$15 0°/o 
В Sbm>'!5 0o/o 
12 18 24 30 36 42 48 54 
Survival (months) 
Figure 4. Survival curves (according to Kaplan and '-leier) of ALL patient,s 
with high % S. (> IS %) and nomai or low % S, (£ IS %). 
Number of patients 
Age, median 
(range) 
WBC, median 
(range) 
Complete remission 
Estimated median rémission 
duration (range) 
Estimated median survival 
(range) 
".
 sbn s 15 % 
11 
18 year 
(13-28) 
10 5 χ 10 9/1 
(0 6-71 0) 
10 
33 months 
(2 - 37 t) 
51 months 
(7-51) 
S Sbr > 15 % 
12 
20 year 
(14-69) 
12 6 χ 10 9/1 
(0 6-477) 
7 
12 months 
(1 - 22) 
5 months 
(2-24) 
NS« 
NS 
NS 
P=0 016 
P= 0 006 
ι NS = non significant 
+ = still alive 
Table 2. Characteristics oj 
si Tied accordinq to the % S, J v
 Dm 
23 adult patient with ALL at diagnosis subclas-
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The % S. in ANLL was not related to the likelihood of achieving a complete 
remission, ι e complete remission was obtained in 9 out of 15 patients with 
initial % S, above the median value and in 11 out of 16 patients with a 
% S. below the median. 
The median survival of 31 patients with ANLL of which the % S. could be de­
termined was 13 months The % S. at diagnosis in ANLL was not related to re­
mission length or survival. 
On the other hand, in 12 out of 23 ALL patients a high % S. (> 15 %) corres­
ponded evidently with an unfavourable prognosis In ALL-patients with a % S, 
> 15 7c the median length of remission was 12 months, while in patients with 
a % S. < 15 % the median remission duration was 33 months (p = 0.016). The 
median survival in both groups was also significantly different, respectively 
5 and 51 months (p = 0.006)(Figure 4). Table 2 summarizes the differences 
between the two groups of ALL-patients with regard to remission rate, length 
of remission, survival, white blood cell count and age. Remission duration 
and survival were significantly related to the percentage of S-phase cells in 
the bone marrow at diagnosis. 
DISCUSSION 
Bone marrow aspirates may contain considerable amounts of nucleated cells, 
derived from peripheral blood (1,2,6). This contamination has negatively af­
fected results of bone marrow studies with regard to proliferation kinetics 
and may partly account for the discrepancy and the great variation of the pre-
therapeutic S-phase compartment in leukemias as reported in literature (11,12, 
13,14,15). The influence of peripheral nucleated cells in bone marrow aspira­
tes upon the results of cytokinetic studies was recently discussed by Hidde-
mann et al (2) and Dosik et al (16), who advocated the use of bone marrow 
biopsies instead of aspirates to circumvent this problem. As shown in the pre­
sent study, cytokinetic data of the bone marrow could be obtained, in 82 out 
of 106 patients with acute leukemia and in all 25 healthy controls from bone 
marrow aspirates, applying a correction procedure for peripheral blood admix­
ture. A high F , hampered a reliable determination of the % S, in only 8 pa­
tients. 
The mean % S. in 25 healthy controls was 11 3 % and 11.0 % as determined 
with respectively DNA-FCM and H-thymidme autoradiography. The mean LI of the 
myeloid cell series and erythroid cells were respectively 9.1 % and 27.1 %. 
In the majority of patients with ANLL the % S, was of the same order of mag-
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nitude as the LI of normal myeloid cells and in 3 patients with AEL the % S. 
was as high as the LI of the normal erythroid precursors. 
These values suggest a normal cell proliferation rate in a majority of patients 
with AML and AEL. 
On the other hand in 12 out of 23 patients with ALL at diagnosis and in 6 out 
of 11 patients at relapse the % S. was much higher compared to normal, which 
corresponds with an unfavourable prognosis in regard to remission duration and 
survival. In ANLL patients these findings could not be demonstrated, whereas 
in both ANLL and ALL patients no relation was found to exist between °i S. and 
age, or % S. and initial white blood eel I count. In addition, there was no 
significant difference between the % S, at diagnosis and the % S. at relapse 
in both groups of patients. 
The unfavourable prognosis of a high % S, with respect to remission dura-
tion and survival in patients with ALL is consistent with findings reported 
by some other investigators (17,18). 
An initially rapid cell turnover, causing a rapid increase in cell number at 
relapse and the quick development of resistance to chemotherapeutic agents 
by rapidly proliferating cells, are postulated as probable explanations for 
this observation. Anyhow, one would anticipate that patients with a high 
% S. would require quite different treatment from those with a normal or low 
*
 Sbm· 
The frequency of aneuploidy observed with DNA-FCM in the present study 
(7.5 % of ANLL, and 8.0 % of ALL patients at diagnosis) is lower than the 
16.5 % incidence reported by Barlogie et al (19). On the other hand, in ALL 
patients at relapse a 42.1 % of aneuploidy was noticed suggesting a growth 
advantage of cells with high degree chromosomal aberrations in ALL. 
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ADDENDUM 
Correction of data obtained in bone marrow aspirates for deviations due 
to peripheral blood admixture is subjected to the "propagation of errors" in­
herent to the figures used for the calculation (20). 
Generally speaking if a result R depends on measurements M according to the 
equation (1). 
R = f (Mj, M 2, M3 M n) (1) 
the standard error Δ R can be calculated according to the function (2) 
( Ä R )2 = 2 (дм. ^ ) 2
 +
 2 î Δ Μ2, υ . . « « . (2) 
1 = 1 1
 ÓM. ι j+i 1 J 6M. 6M, 
where Δ M is the standard error of measurement M,. 
The second term of covariates is discarded in the present study, because these 
parameters can be expected to be uncorrelated. 
The standard error of % S, was calculated with use of experimentally deter­
mined standard deviations of the individual variables such as the nucleated 
cell count (NC), the hemoglobin content (Hb) and the percentage of S-phase 
cells (S). The functions which were found to exist for the various parameters 
are expressed in the formulas (3), (4) and (5): 
Δ NC = 0.107 NC(·52) + 0.01 NC (3) 
Δ Hb = 0.007 Hb* 1· 5' + 0.05 (4) 
Δ S = 0.2 + 0.03 S (5) 
The standard error of % S. as function of F . was calculated. 
In figure 5 a plot is given of the expected error in % S. as a function of 
F , , keeping all parameters of the peripheral blood constant. The calculated 
Standard Error (SE) at various F .-values (line) correlates closely to an 
actual set of measurements (dots). 
If the F , is 40 % or higher the SE increases progressively beyond 10 percent 
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Figure 5. The relation between the F , and the expected error in the % S, . 
The line indicates expected values, the dots indicate the results 
of an actual set of measurements. 
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ABSTRACT 
Flow cytometric analysis of bone marrow aspirates and blood samples in 42 
patients with chronic myelogenous leukemia (CML) at various stages of their 
disease was performed to determine the size of the S-phase compartment of 
bone marrow and blood. Twenty-five healthy controls were studied for compa-
3 
rative information with both DNA-flow cytometry (DNA-FCM) and H-thymidine 
autoradiography. A correction procedure was applied for peripheral nucleated 
cell admixture in bone marrow aspirates. 
The fraction of peripheral nucleated cells in bone marrow aspirates (F . ) 
in individual patients was considerable, especially in those with a very 
g 
high white blood cell count (> 100 χ 10/1). 
The size of the S-phase compartments of bone marrow (% S. ) in patients 
with CML at diagnosis and in patients at apparent hematological remission is 
of the same order of magnitude as in normal bone marrow. However, in 3 out 
of 4 patients at malignant metamorphosis in which the % S, could be reliably 
determined, this percentage was signiciantly higher than normal (p = 0.013). 
In 4 out of 11 patients at malignant metamorphosis aneuploidy was noticed. 
From these findings it is concluded that bone marrow cell proliferation 
in CML patients at diagnosis and during apparent remission is not essentially 
different from normal. However, at malignant metamoprhosis changes occur in 
ploidy level or proliferative activity. 
DNA-FCM provides means for early detection of malignant metamorphosis in CML. 
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INTRODUCTION 
Cytokinetic studies in patients with chronic myelogenous leukemia (CML) at 
various stages of their disease are commonly performed with tritiated thymi-
dine autoradiography of blood samples and bone marrow aspirates (1). Recently 
it was demonstrated that bone marrow aspirates in patients with leukemia may 
be contaminated with peripheral nucleated cells (2), constituting a major 
error factor in cytokinetic studies of bone marrow (3,4)· 
In the present study the amount of peripheral nucleated cells in bone mar-
row aspirates of patients with CML at various stages of the disease was deter-
mined, and the S-phase compartment of bone marrow and blood investigated with 
DNA-flow cytometry (DNA-FCM). The results are compared with data obtained in 
healthy controls who where studied with both DNA-flow cytometry and tritiated 
thymidine autoradiography. 
MATERIALS AND METHODS 
Patients 
DNA-FCM was performed on bone marrow aspirates and blood samples in 42 
patients with CML and 25 healthy controls. 18 Patients were studied at diag-
nosis, 13 patients in apparent hematological remission and 11 patients at 
malignant metamorphosis of the disease. All patients received busulfan as 
remission-induction and maintenance therapy. 
Malignant metamorphosis was defined by a rising white blood cell count with 
increasing numbers of immature cells, associated with a fall in Hb-level, 
occurring in spite of intensified treatment. 
Sample processing 
From sternum or posterior iliac crest 0.5 - 1.0 ml bone marrow was aspi-
rated and anticoagulated with 1.0 ml acid citrate dextrose (ACD formula A). 
A venous blood sample was taken from an antecubital vein. The Hb-content and 
cell number were measured in both bone marrow and blood-samples. 
Staining was performed by adding 10 nucleated cells to 5 ml hypotonic 
ethidium-bromide solution (0.1 % trisodium citrate, 25 mg/1 ethidium bromide), 
5 
according to Krishan (5). The relative fluorescence of about 10 cells was 
measured in a ICP-11 pulsecytophotometer (Phywé Company, FRG). Distributions 
of DNA-content were analyzed utilizing the method described by Baisch et al 
(6). 
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The median coefficient of variation for the G,-compartment was 3.2 % (range 
2.2 % - 5.3 %). 
Сот есЫоп for peripheral blood admixture in hone marrow aspirates 
The fraction of contaminating peripheral nucleated cells present in bone 
marrow aspirates was calculated as recently described (2,1). Briefly, this 
method is based on the observation that almost all hemoglobin (or erythrocy­
tes) present in a bone marrow aspirate, is derived from peripheral blood. 
Consequently, determination of hemoglobin content and the number of nucleated 
cells in the blood and bone marrow samples permits the calculation of the 
fraction of nucleated cells in the aspirate originating from peripheral blood, 
according to the formula: 
NC . HB 
F - Pb χ asp 
P b N C
a
c n Hbnh asp pb 
where NC . and NC stand for the nucleated cell count respectively in peri­
pheral blood and bone marrow aspirate and HB . respectively Hb for hemo­
globin content in peripheral blood and aspirate. 
Consequently, the percentage of S-phase cells in the bone marrow compartment 
can be deduced from the percentages of S-phase cells in blood and bone marrow 
aspirate, according to the formula: 
% S
a c n
 - (F . χ % S . ) %
 s
 _ asp v pb pb^ 
b m
 " 1 - F к Pb 
where % S. , % S , and % S . stand for the percentages of S-phase cells in 
respectively bone marrow compartment, bone marrow aspirate and peripheral 
blood. 
Calculation of the % S. in bone marrow aspirates of which the F . amounts 
to more than 40 % is not reliable, as appears from an error-analysis (see 
Addendum). Therefore these bone marrow aspirates were rejected for calculation 
of the % S.
m
. bm 
Tritiated Thymidine Autoradiography 
In addit ion to DNA-FCM, bone marrow aspirates of 25 healthy controls were 
3 
studied with Η-thymidine autoradiography. To 100 ul of the anticoagulated 
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з 
bone marrow aspirate, 0.5 jCi Η-thymidine (Radiochemical Centre Amersham, 
specific activity 5 Ci/mmol) was added and incubated for 60 min at 370C. 
Smears were prepared, air dried, fixed in absolute methanol and stained with 
May-Grünwald Giemsa. The slides were covered with polyvynilidenechloride to 
prevent chemography of the overlayered Illford L4 photographic emulsion (7). 
Autoradiographs were examined after an exposure of 14 days at 4 С The per­
centage of labeled cells was determined by counting 2000 nucleated cells. 
Cells with more than 4 grains were considered to be labeled. 
The Labeling Index (LI) of myeloid cells (from blast to polymorphs) and ery-
throid cells were determined separately and corrected for contributing peri­
pheral myeloid cells, according to the formula: 
LI-M 
LI-M. = a s p 
bm " ~ И
р
рЬ
 x %
 V 
where LI-M, and LI-M stand for labeling index of myeloid cells in bone bm asp 3 
marrow compartment and bone marrow aspirate respectively, and % M . stands 
for the percentage of granulocytes in blood as determined with the Hemalog-D 
(Technicon). The determination of the LI of the various subclasses of the mye­
loid cells was omitted since an accurate distinction of these subclasses is 
not quite possible on autoradiographs. 
Statistioal methods 
Analysis for differences in size of S-phase compartments between the va­
rious groups of patients was performed utilizing Students'-t-test. 
RESULTS 
Patient aharaoveristics and the fraction of periphero.Z nucleated cells in 'bone 
marrow aspirates (F .) 
Table 1 summarizes the clinical characteristics of the CML-patients stu­
died. The median white blood cell count (UBC) at diagnosis, at hematological 
remission and at malignant metamorphosis were respectively 132.1, 15.7 and 
g 
23.0 χ 10/1. In patients with malignant metamorphosis the percentage of blast 
cells ranged from 15 to 75 % (median 29 %). 
As may be evident from the formula, one may expect a high F . especially 
in patients with high WBC counts. In 11 out of 13 patients having WBC counts 
g 
of more than 100 χ 10 /1 the F . exceeded 40 % indeed, while this was only the 
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Median Median 
. Age WBC 0 
"
 S e x
 years 109/1 
M/F (range) (range) 
Median Meüian 
BM -blast fob* 
(range) (range ) 
It Diagnosis 18 12/6 36 132.0 2 51 
(24-79) (15 9-500) (1-7) (25-100) 
At " R e i n s s i o n " 13 11/2 39 15 7 1 11 
(28-56) ( 5 9 . 0 - 4 . 7 ) (1 -5 ) (2-100) 
At Malignant 
Metamorphosis 11 9/2 53 23.0 29 31 
(21-64) (10 3-137.6) (15-75) (8-100) 
о WBC = White Blood Cell Count 
+ BM = Bone marrow 
χ Fpb = Fraction of peripheral nucleated cells in bone 
narrow aspi rates 
Table 1. Characveristics of the patients with СУХ ас different disease stages 
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Figure 1. The .relation between the F , and WBC count in patients with CML. 
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Median 
Mean 
SD 
Range 
3H-th 
LI(.) 
Myeloid 
Cp11 s 
9 2 
9 1 
2 1 
8 7-14 5 
/mi dine Autorad 
LI(%) 
Ery thro id 
Cells 
27 0 
27 1 
4 S 
17 0-34 7 
1 0 graphy 
HC-) 
Total 
BM 
10 8 
11 0 
1 9 
6 5-13 9 
Flow 
i S 
Total 
3" 
11 2 
11 3 
1 5 
8 4-14 
DNA 
Cyt 
6 
onetry 
, S 
PeriDh 
Blood 
2 0 
2 0 
0 5 
1 6-3 1 
roù^e ¿. The C—rhiiif "сто}rír"P}Íh ir" 'l· hpni'hy "ortvoZ 
NORMALS CML CML CML 
(n=25) Diagnosis .Remission' Malignant (n = 18) (n = 13) metamorphosis (n = 11) 
"'Laure 2. The F in healbhu controls and vatiente 
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case in 8 out of 29 patients with WBC counts below 100 χ 10 /1 (Figure 1). 
Consequently, in the majority of patients with CML at diagnosis (12 out of 
18 patients) bone marrow aspiration yielded cellular material which did not 
represent the cellular composition of the bone marrow compartment. In these 
patients the median F . was 51 % (range 25 - almost 100 ") whereas during 
hematological "remission" or at malignant metamorphosis the median F, was 
11 % respectively 31 % (Figure 2). In healthy controls the median F was 
15 % (range 2 - 36 %). 
The S-phaoe aompai'Lment in normals 
3 
The cytokinetic data obtained with DNA-PCM and Η-thymidine autoradiogra­
phy in 25 controls are summarized in Table 2. 
3 
Ihe median Η-thymidine LI of the total bone marrow (corrected for peri­
pheral blood admixture) was 10.8 % (mean 11.0 + 1.9 % SO), the median LI 
of all myeloid cells in the bone marrow compartment was 9.2 " (mean 9.1 + 
2.1 %), and of the erythroid cells 27.0 (mean 27.1 + 4.8 %). 
The median percentage of S-phase cells in the total bone marrow determined 
with DNA-tlow cytometry (% S b m) was 11.2 % (mean 11.3 + 1.5 %). 
DNA-FCM of normal blood reveals the presence of a median percentage of 
"S-phase" cells of 2.0 % (mean 2.0 + 0.5 % ) . However, this percentage must 
be considered as partly artefactual, because it is caused by interference 
of the relative large amount of erythrocytes in blood samples. Consequently 
S-phase cells in paripheral blood were supposed to be present only, when 
the % S . exceeded a minimum threshold of 3.0 %. pb 
The S-phase compartment in blood and bone marrow in patients with CML 
The results of marrow and blood kinetic studies are shown in Figure 3, 
with comparative information obtained from normal bone marrow. 
Since the F . exceeded 40 % in 12 out of 18 patients with CML at diagnosis, 
the 7c S. could be evaluated reliably in 6 patients only. 
The median % S, in these 6 patients was 12.8 % (mean 13.2 + 2.2 % ) , whereas 
the median % S . of all 18 patients at diagnosis was 9.2 % (mean 9.1 + 2.0 %). 
In 11 patients with CML at apparent remission the median % S, was 11.6 % 
(mean 12.4 + 1.7 %). The median % S , in these patients was 4.1 % (mean 4.4 
+ 1.5 %). The % S, in CML patients at diagnosis and at apparent remission 
are not significantly different from normal. 
In 4 out of 11 patients at malignant metamorphosis, DNA-FCM revealed the 
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BM PB ВМ PB ВМ PB ВМ PB 
NORMALS CML CML CML 
Diagnosis „Remission" Malignant 
metamorphosis 
Figure 3. The percentages of cells in S-phase in bone narrow (BM) and blood 
(PB) in CML patiente at different diseane stages. 
presence of cells with an abnormal DNA-content (aneuploidy). In only 4 out 
out of 
0.013) 
of 7 remaining patients the % S. could be reliably determined. In 3 
these 4 patients the » S, was significantly higher than normal (p 
i.e. 19.3, 18.4 and 17.1 % (median 17.7 %). 
The median % S . in 8 patients at malignant metamorphosis was 10.2 % and 
varied from 5.6 % - 16.5 %. In one patient with aneuploid cells in the bone 
marrow,this abnormality could not be demonstrated in the blood. 
DISCUSSION 
The present study was undertaken to determine the S-phase compartment of 
blood and bone marrow in patients with CML, taking into account the amount 
of peripheral nucleated cells in the aspirate. The results of this analysis 
show that the fraction of peripheral nucleated cells in bone marrow aspirates 
may be considerable in CML-patients, especially in those with a high WBC 
g 
(> 100 χ 10/1) as is usual in about 80 % of the patients at diagnosis (8). 
Studies in CML-patients, in which bone marrow cell characteristics are quan­
tified therefore are more or less hampered by this artefact. This conclu­
sion is consistent with the recent findings of Dosi к et el (4), who showed 
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that cytokinetic data derived from bone marrow aspirates are less reliable 
than those obtained from bone marrow biopsies. These authors supposed peri­
pheral blood admixture in bone marrow aspirates to be the explanation for 
all discrepancies and advocated the use of cell suspensions derived from 
bone marrow biopsies for cytokinetic studies of bone marrow. Nevertheless, 
it could be shown in the present study that corrected cytokinetic data can 
be calculated reliably from bone marrow aspirates, in all 25 healthy con­
trols and in 21 out of 28 CML-patients with a WBC count lower than 100 χ 
g 
10 /1. Recently, we obtained similar results in patients with acute leukemia 
(9,10). 
The variation in the F . in bone marrow aspirates from patients with CML 
at diagnosis did not result however in a large underestimation of the S-phase 
compartment in bone marrow, because at diagnosis the " S, and the % S , in 
CML approximate each other rather closely. 
The similarity of the X S, in normals and patients with CML at diagnosis 
and at remission, is accordant to presumed normal cell proliferation in CML 
(11,12,13). On the other hand in patients studied at malignant metamorpho­
sis the % S, was higher than normal in 3 out of 4 patients, whereas in 4 out 
of 11 patients aneuploidy was noticed at this disease stage. The changes in 
both proliferation pattern and ploidy level of hematopoietic cells in CML 
patients at malignant metamorphosis, supports the suggestion that this dis­
ease-phase results from the evolution of new clones of neoplastic cells 
with an apparent growth advantage over normal cells and chrome,phase CML 
clones (14,15,16). Moreover it indicates that flow cytometry may be applied 
as a useful tool for early diagnosis of malignant metamorphosis in CML. 
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ADDENDUM 
Correction of data obtained in bone marrow aspirates for deviations due to 
peripheral blood admixture is subjected to the "propagation of errors" inhe-
rent to the figures used for the calculation (17). 
Generally speaking if a result R depends on measurements M according to 
the equation (1) 
R = f (Mj, M2, M3 Mn ) (1) 
the standard error R can be calculated according to the function (2). 
(ÄR)2 = S
 ( ΔΜ. ÍE_)2 + 8 . r Ä M 2 . . ¿ R ^ iR_ (2) 
i = l 1 <SM. 1 j+i ^ 6Mi óMj 
where ΔΜ is the standard error of measurement M,. 
The second term of covariates is skipped in the present study, because these 
parameters can be expected to be incorrelated. 
The standard error of % S. was calculated with use of experimentally deter­
mined standard deviations of the individual variables such as the nucleated 
cell count (NC), the hemoglobin content (Hb) and the percentage of S-phase 
cells (S). The functions which were found to exist for the various parameters 
are expressed in the formulas (3), (4) and (5): 
Δ NC = 0.107 Nc(- 5 2 ) + 0.01 NC (3) 
Δ Hb = 0.007 Hb ( 1 - 5 ) + 0.05 (4) 
Δ S = 0.2 + 0.03 S (5) 
The standard error of % S. as function of F . was calculated. 
Figure 4 shows the expected error in % S as a function of F . , keeping all 
parameters of the peripheral blood constant. 
The calculated Standard Error (SE) at various F .-values (line) correlates 
closely to an actual set of measurements (dots). If the F , is 40 " or 
higher the SE increases progressively beyond 10 percent. 
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Figure 4. The relation betueen the F , and the expected error in the % S, . J
 po r bm 
The line indicates expected values, the data, the results of an 
actual set 'ор measurements. 
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CHAPTER VII 
CYTOKINETIC CHANGES AFTER CYTOSINE ARABINOSIDE IN 
ACUTE NON-LYMPHOCYTIC LEUKEMIA 
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ABSTRACT 
Changes in the S-phase compartment of blasts were measured after intrave-
2 2 
nous push injections of cytosine-arabinoside (Ara-C, 100 mg/m , 380 mg/m or 
1000 mg/m body surface) in 11 patients with acute non-lymphocytic leukemia 
At several intervals after Ara-C injection, blood and bone marrow samples 
3 
were taken for autoradiography, DNA-flow cytometry and Η-thymidine incorpo­
ration 
The data obtained from the bone marrow aspirates were corrected for peri­
pheral blood admixture In untreated patients the three methods correlated 
very well. The perturbation of the cell-cycle after Ara-C administration 
shows for each method a specific pattern ^аЬеІгт гпаьае^ reached, after an 
initial decrease, pretreatment levels at about 24 h after injection. Recruit­
ment of cells into the cycling compartment could not be demonstrated. ifA-f^ou 
cytometry reveals a significant increase in the percentage of cells with > 2n 
< 4n DNA, with a maximum after about 30 h The discrepancy between autoradio­
graphy and DNA-flow cytometry after Ara-C injection may be due to the pre-
sence of cells arrested in S-phase. d-thjmd ne гпсо*ч?огаЬ~оп increased af­
ter an initial inhibition to about twice pretreatment values at 36 to 40 h 
after injection This observation suggests partial synchronization. Incorpo-
3 
ration of H-thymidine in peripheral nucleated cells correlated well with 
3 
the corrected values of Η-thymidine incorporation in the bone marrow The 
perturbation of the cell-cycle appeared identical in the three different 
dosages used. The observations suggest that 24 h scheduling might be optimal 
for Ara-C given by push-injections 
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INTRODUCTION 
In the treatment of acute non-lymphocytic leukemia (ANLL) cytosine arabi-
noside (l-ß-D-arabinofuranosylcytosine, Ara-C) is one of the major chemothe-
rapeutic agents (1,2). Its cytostatic activity is based on inhibition of DNA-
synthesis by competitive interference of the intracellular metabolite cyto-
sine arabinoside triphosphate with deoxycytidine triphosphate for the enzyme 
DNA-polymerase (3,4,5,6). 
The depression of cellular DNA synthesis caused by intravenous administra-
tion of Ara-C varies considerably between leukemic patients (7,8,9) and may 
be related to individual differences in half-life time of Ara-C in the blood 
(7,8,10) and to differences in the phosphorylating capacity of the leukemic 
cells (3,11). The anti-leukemic effect of a treatment-course depends on the 
dose of Ara-C, the number of injections and the percentage of cells in 
S-phase at the moment of injection (12,13). 
In animal models high dosages of Ara-C cause accumulation of cells in 
S-phase and treatment results are substantially improved when subsequent in-
jections are given at the moment of maximal S-phase accumulation (14,15,16). 
Schedules used in human ANLL are almost completely empirical. Adjustment of 
administration intervals to the moment of maximal S-phase accumulation may 
improve treatment results in human ANLL as well. 
This paper reports the results of a study in which cytokinetic changes 
were investigated in bone marrow and peripheral blood of patients with ANLL 
after intravenous bolus injections of different dosages of Ara-C. 
MATERIALS AND METHODS 
Patients 
Cell-kinetic studies were performed in 11 patients with ANLL before and at 
different time intervals after an intravenous bolus injection of Ara-C. Diag-
noses were confirmed at thw W.H.O. Reference Rentre for Leukemias, Villejuif, 
France and by the Bone Marrow Committee at Rotterdam, The Netherlands. 
Clinical data at the time of investigation are summarized in Table 1. Only 
one patient received previous cytostatic treatment. All patients received one 
9 
intravenous push-injection of Ara-C, respectively 1000 mg/m (3 pat ients) , 
380 mg/m (4 patients)or 100 mg/m (4 pat ients) . 
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lent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Age 
(years) 
53 
60 
31 
63 
53 
41 
10 
40 
34 
24 
44 
Sex 
M 
F 
F 
M 
M 
M 
F 
M 
M 
F 
H 
Morphol ogical 
diagnosi s"* 
M 
M 
M 
M 
M 
M 
M 
4 
M 
M 
M 
1 
Initial UBC 
(χ io 9/i; 
75 
6 
50 
66 
7: 
127 
16 
96 
β 
16 
26 
% Blasts 
(Pb) 
70 
1 
69 
32 
89 
69 
17 
83 
25 
60 
30 
% Blasts 
(lm) 
73 
50-
B8 
90 
74 
93 
45Î 
95 
90 
71 
70 
C l a s s i f i c a t i o n according to the French-American-Brit ish (FAB) Co-operative Grouo 
Classification (29) 
t Remainder are oathological (oro)myelocytes 
t Bone marrow contained 17 * erythropoiesis 
Table 1. Patient akavaateristias 
Sampling 
Bone marrow aspirates and peripheral blood samples were collected in buf-
fered acid citrate dextrose solution (ACD formula A, pH 7.4). In one patient 
(no. 11), for technical reasons, only peripheral blood was monitored. Cells 
were washed in order to prevent fibrin formation during incubation. Since the 
presence of erythrocytes did not interfere with the measurements, no proce-
dures were used to remove erythrocytes from the samples. 
Measurement of the labeling index 
3 
To 100 vl of blood or bone marrow sample, 0.5 yCi Η-thymidine (Radioche­
mical Centre Amersham, specific activity 5 Ci/mmol) was added and incubated 
for 60 min at 37 С Smears were prepared, air-dried, fixed in methanol and 
stained with May Grünwald-Giemsa. The slides were covered with polyvynil-
idenechloride to prevent chemography of the overlayered Ilford L4 photogra-
phic emulsion (7). Autoradiographs were exmined after an exposure of 14 days 
at 40C. The percentage of labeled cells was determined by counting at least 
2000 nucleated cells. Cells with more than 4 grains were considered to be 
labeled. 
36 
Measuremenb of D'ìA-content with flow cytometry. 
The nuclear DNA of about 10 cells of each blood or bone marrow sample was 
stained by adding a small volume of the cell-suspension to 10 ml hypotonic 
ethidium-bromide solution (0.1 % tri-sodium citrate, 25 mg/1 ethidium-bromide) 
5 
according to Krishan (18). The relative fluorescence of about 10 individual 
cells was measured in an impulse cytophotometer (ICP-11, Phywé). To determine 
the percentage of cells containing > 2n < 4n DNA, the histograms were analysed 
according to Göhde (19) with a computer program as described by van Egmond 
and Hillen (20). 
Measurement of Η-thymidine incorporation 
Blood and bone marrow samples were diluted in medium 199 (Flow Laboratories) 
buffered with 10 mM Tris (pH 7.4) and supplemented with 10 % heat inactivated 
fetal calf serum (Flow Laboratories, Lot. 2919107) to a final cell concentra­
tion of 10 nucleated cells per ml. Four aliquots of 1 ml were incubated with 
2 ViCi Η-thymidine (specific activity 5 Ci/mmol) for 60 min at 370C. 
The incubation was stopped by adding 2 ml ice-cold medium with an excess 
of unlabeled thymidine. The cells were collected on glass fiber filters 
(Schleicher and Schuil No. 9 ) , washed with water and precipitated with 1 M 
perchloric acid. The total amount of radioactivity in the perchloric acid pre-
cipitable fraction was counted in a liquid scintillation counter (LKB 81000) 
with a counting efficiency of about 30 %. 
Correction for peripheral admixture and error analysis 
The fraction of contaminating peripheral nucleated cells, present in the 
bone marrow aspirates, were calculated according to Holdrinet et al (21). This 
method is based on the observation that almost all red cells, present in a 
bone marrow sample, are derived from peripheral blood admixture. Determination 
of hemoglobin content and the number of nucleated cells in the blood and bone 
marrow samples allows the calculation of the fraction of nucleated cells in 
the aspirate originating from the bone marrow compartment (F. ), according to 
the formula: 
pb a 
Fhn, = * 
NC Hb, 
a pb 
where NC .. and NC stand for nucleated cell count in peripheral blood and 
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aspirate respectively and Hb . and Hb respectively stand for hemoglobin con­
tent in peripheral blood and aspirate. 
The cell-kinetic data (D) of the bone marrow compartment are calculated 
from the measurements on both the aspirate and the peripheral blood, accor­
ding to 
Jbm 
(^ ЬпЛь 
bm 
where D stands for labeling index, percentage cells with > 2n < An DNA or 
3 
Η-thymidine incorporation respectively. 
The error in F. is a function of the individual errors of cell counts and 
hemoglobin measurements, determined in bone marrow aspirate and peripheral 
blood and can be calculated with the formula (22): 
ДО = VMVÑ) 
where Эо/Эх. = first derivative to the i th variable; Δχ. = standard error of 
the i th variable; D = any parameter to be calculated from the variables. 
1 г 3 4 5 6 7 
Figiœe 1. Fraction of nueleated cells in the bone marrou aspirates originating 
from the bone marrow compartment (F, ) . 
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RESULTS 
Peripheral blood aanixLure in bone via^rou) aspirates 
The fraction of peripheral nucleated cells in the bone marrow aspirates 
varies considerably, even within the same patient (figure 1). Four aspirates 
contained more than 50 % peripheral nucleated cells and the relative error on 
the F. exceeded 10 % in these cases. These samples were therefore excluded 
from further evaluation. 
Aaouraoy of data 
Errors on all data were calculated as described under methods. For labeling 
indices over 6 % the relative error is about 15 %. Flow cytometric determina­
tion of the percentage S-phase cells is more accurate, for values over 4 %, 
the relative error is less than 10 %. The relative error is also smaller than 
10 % for values of thymidine incorporation over 1000 counts/min/10 cells. 
For data below these limits the relative errors showed a rapid increase. 
Bone marrow S-phase aompartment before treatment 
The relative number of proliferating cells before Ara-C injection differs 
between patients. The percentage S-phase cells determined by labeling index 
varied from 3.4 to 20.5 %. The S-phase compartment as determined by DNA-flow 
cytometry ranged from 4.7 to 21.6 %. Correlation between these methods was 
good (correlation coefficient 0.93). In one patient (No. 9) the number of 
S-phase cells could not be calculated from the DNA-histogram because of poly-
3 
ploidy. Incorporation of Η-thymidine ranged from 4400 to 59.700 counts/min/ 
fi ì 
10 cells. For all patients, except one (No. 2) Η-thymidine incorporation 
correlated with the labeling index (correlation coefficient 0.87, patient 2 
omitted) and with flow cytometry (correlation coefficient 0.93, patient 2 
omitted). 
Perturbation in S-phase compartment of bone marrow cells after Ara-C injection 
Changes in labeling index. Labeling indices determined 7 h a f t e r Ara-C 
administration were s i g n i f i c a n t l y below pretreatment values in a l l évaluable 
pat ients. The data, found 23 h af ter i n jec t i on , were comparable to pretreat-
ment values. Labeling indiced obtained af ter Ara-C administration did not 
exceed s ign i f i can t l y pretreatment values, except in patient No. 3 (Table 2). 
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Doses Ara-C Hours after Ara-C a d m n i s t r a M o n 
Patient (mg/m 2) 0 1 7 23 31 47 70 
1 
2 
3 
4 
5 
6 
7 
β 
9 
10 
11 
1000 
1000 
1000 
380 
380 
380 
380 
100 
100 
100 
100 
12 О 
20 5 
б 8 
3 4 
18 1 
13 4 
8 2 
19 0 
3 9 
12 4 
» Aspirate contained more than 50 % peripheral nucleated cells 
Table 2. Changes in labeling index in bone marrow cells after Ara-C admini­
stration. 
ι ent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Doses Ara-
(mg/m 2) 
1000 
1000 
1000 
380 
380 
380 
380 
100 
100 
100 
100 
-с 
0 
11 0 
21 6 
9 8 
4 7 
14 3 
14 7 
9 2 
17 4 
polyploidy 
11 4 
Hours 
] 
16 
I 
3 
after 
7 
7 3 
19 2 
4 5 
4 0 
10 3 
6 1 
9 4 
. 
7 8 
Ara-C a 
23 
10 0 
6 7 
17 7 
t» 
13 3 
18 0 
14 7 
dmim stration 
31 
11 1 
27 2 
14 0 
8 3 
-
19 3 
13 6 
23 8 
16 0 
47 
17 9 
18 2 
12 3 
6 8 
16 4 
19 1 
10 5 
Aspirate contained more than 50 % peripheral nucleated cells 
Table 3. Changes in percentage bone 'narrow cells with > 2n < 4n DNA after 
Ara-C administration. 
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1 0 
0 0 
0 9 
4 0 
1 6 
0 0 
2 5 
5 2 
1 3 
. 
0 0 
3 9 
8 1 
3 0 
12 2 
» 
8 7 
16 9 
6 1 
12 2 
11 7 
13 4 
16 4 
3 4 
о 
13 2 
6 0 
17 2 
. 
9 5 
14 2 
12 0 
13 9 
3 3 
13 7 
16 2 
6 7 
Chanjcs in flou aytomptvia measuvemcntc. A slight decline in the percentage 
S-phase cells was observed 7 h after Ara-C injection. After 23 h in 5 out of 
7 évaluable patients, these values returned to pretreatment levels and showed 
a further increase thereafter. In all 8 patients, évaluable 31 h after injec-
tion the percentage S-phase cells exceeded significantly pretreatment values, 
and tended to decline thereafter (Table 3). 
¿ 3 
Charujes in H-ік^гпгагпс inaorpor-atiori. Η-thymidine incorporation was sig­
nificantly decreased 1 and 7 h after Ara-C administration. The incorporation 
measured 23 h after injection was comparable with the incorporation before 
Ara-C administration. A marked increase was observed thereafter in most pa­
tients. In 7 our of 10 patients maximal values obtained ranked higher than 
pretreatment values (1.5 to 2.5 times higher). In patient 4, the elevation 
may have been missed as the 31 h sample could not be analysed. 
In patient No. 2, thymidine incorporation did not return to the pretreatment 
level. In this case, thymidine incorporation before Ara-C was extremely high 
and not proportional to the percentage of S-phase cells. In patient No. 10, 
only a slight increase was observed. The results are given in Table 4. 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
И 
Doses Ara-C 
(mg/m2) 
1000 
1000 
1000 
380 
380 
380 
380 
100 
100 
100 
100 
0 
16 ,A67 
59,715 
11,027 
4436 
14,343 
19,735 
10,772 
24,957 
6230 
18,300 
1 
534 
1503 
7 
7405 
8275 
2033 
1195 
2057 
4746 
4495 
^ 
1038 
7613 
23 
25,776 
3917 
15,329 
+ 
14,764 
17,667 
20,358 
19,125 
31 
41,116 
20,759 
17,337 
± 
-
35,512 
19,315 
44,019 
7543 
8119 
47 
42,428 
17,775 
14,467 
3985 
26,338 
31,769 
12,325 
70 
8818 
• Counts/min/10 cells 
^ Aspirate contained more than 50 S peripheral nucleated cells 
t Sample contaminated with bacteria. 
3 . . . «> 
Table 4. Changes in H-thymidine inaomoration in bone marrow cells after 
Ara-C administration. 
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Doses Ara-C Hours after Ara-C administration 
Patient (mg/m2) 0 1 7 12 23 27 31 
8 
9 
10 
11 
1000 
1000 
1000 
380 
380 
380 
360 
100 
100 
100 
100 
565 
6496 
1490 
676 
554 
B708 
3741 
5378 
1982 
370 
2699 
259 
279 
955 
281 
909 
878 
473 
340 
4057 
1472 
569 
910 
2045 
657 
3083 
848 
1456 
837 
11,272 
5125 
3596 
3936 
2935 
4823 
1604 
953 
1996 
2185 
Ζ 
1397 
10,922 
7125 
6403 
1640 
1054 
1626 
1836 
1078 
1283 
6509 
5535 
2294 
0.97 
0 99 
1118 0 96 
0 Θ1 
0 96 
0 89 
0.98 
0.96 
0 98 
t Correlation coefficient of Η-thymidine ιncoroorati on in bone marrow and peripheral blood 
î Sample contaminated with bacteria 
3 Table 5. Changes in H-thymid-ine inoorporation in peripheral blood aclis after 
Ara-C administration. 
Cyiokinetic measurerients in peripheral blood 
As the percentage of p ro l i fe ra t ing cel ls in peripheral blood is mostly very 
low, re la t ive errors in labeling inaices and flow cytometric data are too 
3 
high for accurate measurements. Η-thymidine incorporation is a more sensit ive 
parameter and in 10 out of 11 patients i t was high enough to produce évaluable 
3 
resu l ts . Only in one patient (No. 10) Η-thymidine incorporation was too low 
for evaluation (less than 500 counts/min/10 c e l l s ) . In a l l patients thymidine 
incorporation i n peripheral blood showed the same pattern as in bone marrow, 
although at a lower l e v e l . Correlation between thymidine incorporation in bone 
marrow and peripheral blood in individual patients is expressed in t h e i r corre­
l a t i o n c o e f f i c i e n t s , ranging from 0.81 to 0.99 (Table 5). 
Effect of the dosage of Ara-C 
The perturbation of the cel l-cycle by the three d i f f e r e n t dosages Ara-C 
? ? ? 
(100 mg/m , 380 mg/m , 1000 mg/m ) shows no essential differences. 
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DISCUSSION 
As is shown in th is study, the percentage of nucleated cel ls derived from 
the peripheral blood in a bone marrow aspirate may vary considerably To our 
knowledge, th is contamination was never taken into account in studies about 
c e l l - k i n e t i c changes af ter cytostat ic therapy which may explain f luctuat ions 
in previously published results (23,24,25,26). After el imination of the i n ­
fluence of peripheral blood admixture, the cytokinet ic data of the bone mar­
row show good s i m i l a r i t y in a l l patients Furthermore, correction unmasked a 
3 
good correlat ion between H-thymidme incorporation in the bone marrow cel ls 
and in the peripheral nucleated cel ls 
No studies are available which compare the results of autoradiography, DNA-
flow cytometry and H-thyrmdme incorporation of leukemic cel ls before and 
during 48 h af ter Ara-C administration. Before Ara-C i n j e c t i o n a good corre­
l a t i o n exists between the three methods. After Ara-C administration th is 
corre lat ion appeared to be disturbed The differences between the patterns 
obtained with each method provides additional information about the cytokine­
t i c effects of Ara-C. 
After an i n i t i a l decrease, іаЪрІгуд гпагвеч returned to pretreatment 
values. A pronounced increase in the labeling index as described in animal 
models (16) was not observed. Our data confirm the results of Ernst et al 
(23) and Lange Wantzin et al (26) Lampkin et al (25) found a s i g n i f i c a n t 
increase of the labeling index in half of the patients 18 to 24 h af ter Ara-C 
administrat ion. This observation may be caused by d i f f e r e n t amounts of p e r i ­
pheral blood admixture in the bone marrow sample before Ara-C in ject ion and 
the sample obtained 18 to 24 h af ter in ject ion 
The decrease in the percentage S-phase c e l l s , measured with D'A-flow cyto­
metry, was less pronounced than that estimated from labeling indices. Maximal 
values estimated with flow cytometry were found to be about 1.5 times pre­
treatment values The discrepancy between labeling indices and flow cytome­
t r i c data may be explained by the presence of cel ls arrested in S-phase. The 
decrease in the н-ьп-уггаъпе incorporation a f t e r Ara-C in ject ion was propor­
t ional to the decrease in the labeling index. Pretreatment levels were reached 
af ter about 24 h. Thereafter thymidine incorporation showed a further r ise 
to maxima of about twice pretreatment values. Since the labeling indices did 
not increase s i g n i f i c a n t l y , the increased thymidine incorporation may be due, 
for instance, to p a r t i a l synchronization of cel ls in mid-S-phase (27,28). 
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In conclusion, changes suggesting recruitment of leukemic cells by Ara-C were 
not observed; the data are suggestive for the occurrence of partial synchro-
nization; evidence is found for the presence of cells arrested in S-phase af-
ter Ara-C injection. 
Thymidine incorporation in peripheral blood cells showed a close correla-
tion with data obtained in the corresponding bone marrow (Table 5). Therefore, 
incorporation studies in peripheral blood may be a suitable method for moni-
toring the cell-kinetic response in individual patients after Ara-C injection. 
No essential differences in the perturbation of the cell-cycle were obser-
ved with respect to the three different dosages, albeit that a dose of 100 mg/ 
2 
m Ara-C may not always be high enough to produce a sufficient inhibition of 
the DNA-synthesis (24) and to damage S-phase cells irreversibly. The early 
increase of the thymidine incorporation in patient No. 11 may be due to such 
a phenomenon. 
In almost all patients the relative size of the S-phase compartment retur-
ned to pretreatment levels about 24 h after Ara-C administration. Therefore 
treatment schedules with intervals of 24 h will probably result in more effec-
tive cell kill, compared to schedules with shorter intervals. 
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ABSTRACT 
A rapid reproducible method yielding high resolution analysis of DNA and 
protein in human hematopoietic cell samples has been developed by modifi-
cation of the propidium iodide (PI) and fluorescein isothiocyanate (FITC) 
procedure. Cell staining involves sequential addition of each reagent 
(RNase, FITC and PI) to ethanol-fixed cells and requires no centrifugation 
steps. 
Stained cells are analysed in the reagent solutions. Analysis of bone 
marrow samples from multiple myeloma patients showed mixed normal and 
aneuploid populations with the aneuploid cells having a significantly higher 
protein content. 
This approach permitted differential cell cycle kinetic analysis of normal 
and the aneuploid populations. 
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INTRODUCTION 
Analysis of cellular DNA content by flow cytometry (FCM) provides a rapid 
and convenient method for studying cell cycle kinetics (1,2) and population 
ploidy levels (3,4). However, in heterogeneous cell populations such as found 
in human bone marrow, the kinetic patterns are a composite of all hemato-
poietic cell types and cell cycle progression profiles, for subpopulations of 
interest,are not easily derived. Furthermore, when malignant aneuploid cells 
become prominent in the FCM-distributions (5), cell cycle kinetic analysis 
by single parameter DNA content measurements is not possible. 
Protein content of cells reflects in a general way, the metabolic capacity 
of cells and, in most instances, is also a good descriptor for protoplasmic 
mass. Simultaneous FCM analysis of cells stained for both DNA and protein can 
reveal subpopulations of different protein content located throughout the cell 
cycle or within aneuploid cell populations. Additional descriptive information 
such as the nuclear to cytoplasmic relationship (6) and the DNA to protein 
ratios for subpopulations can be determined by FCM (7) and this approach can 
further enhance the analysis of heterogeneous cell populations. 
This report describes a rapid and simplified method for staining hemato-
poietic cells with propidium iodide (PI) and fluorescein isothiocyanate (FITC). 
In contrast to our previous protocol (7), all reagents are added sequentially 
to ethanol-fixed cells and no centrifugation steps are required. 
Staining time is reduced to 10 minutes as compared to 3 h by our previous 
method (7). 
MATERIALS AND METHODS 
Fresh aspirated bone marrow obtained by sternal puncture was diluted in 
ACD-solution (acid citrate dextrose). Red blood cells were removed by centri-
fugation over Percoli (density 1.085 g/tnl ) (Pharmacia Fine Chemicals). The 
supernatant cell suspension was diluted for fold with phosphate buffered 
saline solution containing 13 mM disodium EDTA (PBS-EDTA). White blood cells 
were recovered by centrifugation, and fixed in 70 " ethanol as a total bone 
marrow sample. To avoid cell clumping, cells were first thoroughly resuspen-
ded in 1 ml of cold PBS-EDTA solution and then 3 ml of cold 95 % ethanol was 
added to the cell suspension. 
Alternatively, unfixed bone marrow samples were separated by cell elutria-
tion into subpopulations on the basis of cell size. A small proportion of 
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unfixed cells from each subpopulation was stained for cellular DNA directly, 
by a method similar to that described by Krishan (8) except that ethidium 
bromide (25 ug/ml in 0.1 " sodium citrate) was used in place of propidium 
iodide (PI). The remaining portion was fixed in 70 % ethanol as above. 
For two color DNA-protein staining cell reagents were added sequentially 
to ethanol-fixed cells and no centri fugati on steps were required. Four ml of 
PBS-EDTA solution were added to 0.2 ml of ethanol fixative containing 5 χ 
10 cells. Fluorescein isothiocyanate (1 mg/ml) was initially dissolved in 
absolute ethanol irmedLatclj prior to use, and 0.1 ml of this stock solution 
was added to 10 ml of PBS-EDTA solution. Two-tenths ml of the FITC in PBS-
EDTA solution was added to the cell suspension and after approximately 5 min, 
one ml of propidium iodide (46 ug/ml) was also added to the cell suspension. 
After 2-3 min, 0.2 RNase (1 mg/ml in PBS-EDTA) at room temperature was added 
for at least 1-2 min prior to analysis. Final concentrations of PI, FITC 
and RNase were 8.5, 0.37, and 37 ..g/ml respectively. Stained cells in the 
reagent solutions were analyzed in a Phywé ICP 11 pulse cytophotometer modi-
fied for two-color analysis. 
RESULTS 
Figure 1 (Α-D) and Figure 2 (Α-D) show the DNA-protein distributions res­
pectively obtained by analysis of total bone marrow samples from a normal 
donor and a multiple myeloma patient following staining with PI and FITC. 
The DNA-profiles (Fig. 1A and 2A) each show a G^/G, peak (major peak) repre­
senting a 2c DNA content and a corresponding 4c DNA content (G? + M) popula­
tion based on analysis of the DNA content of nucleated peripheral blood cells 
from a healthy person. However, the arrow in Figure 2A indicate a small but 
significant population of aneuploid cells with an elevated DNA-content. Com­
parison of Figure ID and Figure 2D also shows that this population has a 
higher average protein content than the remaining cells in the 2c-4c DNA-
content range. 
Verification of these observations was made by DNA/protei η analysis of a 
subpopulation of cells from the same myeloma patient obtained following 
cell elutriation. Figure 3 and Figure 4 respectively show composites of the 
DNA profiles of subpopulations of cells from a normal donor (Figure 3) and 
from the multiple myeloma patient (Figure 4). The DNA profiles are arranged 
in order of increasing cell size (front to rear) as indicated by the arrow 
in Figure 3. In general. Figure 4 shows an enrichment of the aneuploid 
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Figure 1. Single paranetev DM (A), protein (В) and tuo parameter 
DNA-protein (С, isometric and D, contour) profiles of Lone 
marrow cells from a normal donor. 
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Fujy.rc 2. Sinjlc parçmeier ISA (A), proLein (в) and tuo parameter Ш4-
protein (C, 'isometric and P, ^or.toy.r) profilca of ceils of 
a total hone marrow sample obtained from a multiple myeloma 
patient. Arrows in A and D indicate position of J
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/G^ cells 
of the ancuploid population. 
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DNA 
'.gure ¿. Composite of ethidium bromide-PM profiles for subpopulations 
of celts obtained by cell elutviation of a normal bone mavrou 
sample. Arrow indicates increasing cell size. 
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DNA 
ligure 4. Composite of etnidiim bromide-D'JA profiles for subpopuLations of 
cells obtained by cell elutriaiion of a bone marrow sample from 
a multiple myeloma patient. Arrow indiaates subpopulation 
described in Figures h and 6. 
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cells in some subpopulations of larger cells, while Figure 3 shows primarily 
an enrichment of the G? + M population with increasing cell size. 
Figure 5 shows the DNA-protein distributions for the subpopulation of 
cells indicated by the arrow in Figure 4. The contour DNA-protein profile 
(Figure 5D) clearly demonstrates the elevated protein content in the aneu-
ploid cells. In fact the protein content of the G^/G, aneuploid cells exceeds 
the protein content levels of the normal S-phase cells of this subpopulation 
having the same DNA content as the aneuploid cells. 
Figure 6 shows the complete DNA-histogram (Figure 6A) and the contour DNA-
protein distribution (Figure 6B) as shown for the myeloma sample in Figure 5. 
The DNA profile shown in Figure 6C was obtained by computer extraction of 
the aneuploid population in Figure 6B based on the elevated DMA and protein 
contents of the aneuploid cells. 
DISCUSSION 
Protocols for cell staining, particularly in routine clinical studies, 
should be simple, rapid, highly reproducible and still provide for quality 
analytical resolution. In this study we have described a useful method for 
DNA and protein staining of human hematopoietic cell samples using PI and 
FITC, respectively. Cells are treated sequentially with the reagent solu-
tions, and rinsing or centri fugati on steps are not required. 
The approach not only increases the rapidity of the method compared to our 
original procedure (7), (i.e. 10 min vs 3 h, respectively), but it also 
minimizes cell clumping and cell loss which can be a particular problem in 
hematopoietic cell samples. 
The two parameter profile obtained by analysis of the PI-FITC stained bone 
marrow sample demonstrates the high quality color resolution that is obtain-
able with this technique. By maintaining the stain concentration at a low 
level, particularly the highly fluorescent FITC, background fluorescence 
remains minimal. However, the dye concentrations are still adequate to 
provide good resolution for detecting abnormalities such as the aneuploidy 
population in the DNA-profile. 
From a clinical standpoint, the procedure appears particularly attractive 
for separating the cell cycle distribution profile of the aneuploid popula-
tion from the normal 2c-4c DNA-content population. In a recent autoradio-
graphic study by Durie et al (9), analysis of the percentage of cells in 
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of cells following cell elutriation of a bone marrow sample ob­
tained from a multiple myeloma patient. 
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obtained by computer extraction (gated analysis) of the aneuploid 
ae I Is. 
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S-phase (tritiated thymidine labeling index, LI) in bone marrow cells of un­
treated multiple myeloma patients provided helpful prognostic information. In 
general that study showed that pretreatment LI > 3 " in high cell mass pa­
tients conferred a poor prognosis compared to patients with LI < 1 *. A recent 
report by Latreille et al (5) revealed a 65 % incidence of aneuploidy in mye­
loma patients and demonstrated that the frequency of myeloma plasma cells 
correlated with the percentage of cells with abnormal DNA-content. 
Based on these studies it appears that simultaneous FCM DNA-protei η analysis 
can further increase the sensitivity of the diagnostic procedure of Durie et 
al (9). By analyzing the kinetic profile of the aneuploid population separa­
te from the other cell populations it is possible to determine, in each in­
stance, which population contributes most significantly to the elevated per­
centage of cells in S-phase. 
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ABSTRACT 
To augment the potential of flow cytometric analysis (FCM) of plasma cells, 
bone marrow aspirates of 12 patients with multiple myeloma (MM) and 3 patients 
with benign monoclonal gammopathy (BMG) were subjected to counterflow centri-
fugation (elutriation) to obtain enriched plasma cell fractions. 
DNA-FCM analysis of these cell fractions in particular patients revealed 
the occurrence of ploidy abnormalities, proliferating plasma cells and multi-
nucleated plasma cells, which was not apparent from DNA-FCM analysis of whole 
bone marrow aspirates'. 
Two parameter DNA/protein-FCM of plasma cell enriched subpopulations addi-
tionally allows discrimination between plasma cells and other bone marrow cells 
by the high protein content of plasma cells, and enables the separate analysis 
of plasma cell proliferative activity. 
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INTRODUCTION 
Introduction of DNA-flow cytometry (FCM) has provided means to obtain 
information about proliferation patterns and ploidy abnormalities in hematolo-
gic malignancies (1). However, application of FCM to the study of plasma cells 
in patients with gammopathies is limited by the heterogeneity of bone marrow 
cells and the low percentages of plasma cells in some cases. 
In the present study, bone marrow aspirates of patients with multiple mye-
loma (MM) and benign monoclonal gammopathy (BMG) were subjected to counterflow 
centrifugation (elutriation) to obtain enriched plasma cell fractions for sub-
sequent FCM-analysis. 
The results in a limited group of patients indicate, that plasma cell en-
richment with elutriation considerably augments the discriminatory potential 
of FCM with regard to various plasma cell characteristics. 
MATERIALS AND METHODS 
Sample processing 
Bone marrow aspirates from 12 patients with MM and 3 patients with BMG, 
were anticoagulated with acid citrate dextrose (ACD formula A) and wahsed once 
with phosphate buffered saline (PBS). Red blood cells were removed by cen-
trifugation over Percoli (density 1.085 g/ml, Pharmacia Fine Chemicals) the 
supernatant cells were washed and resuspended in PBS and subsequently counted. 
Counterflow oentrifugation (elutriation 
A Beckmann elutriator system (J2-21C + JE-6 rotor), adapted with a fine 
scaled speed selector and a 47 PF condensor for improved stability of the 
rotorspeed was utilized in this study. The collecting tubes were filled with 
PBS containing 1 % fetal calf serum, whereupon the cell suspension was slowly 
introduced into the elutriation rotor at a rate of 0.3 ml/min. Elutriation was 
initiated at a rotorspeed of 2500 rpm and a flow rate of 20 ml/min and was 
accomplished by a 5-steps decrease of the rotorspeed to 1000 rpm. A T-tube 
mounted up the effluent line enabled a small sample stream to pass an elec-
tro-optical scatter unit, which permitted a continuous control of cellnumber 
and cellsize in the elutriator effluent during the whole procedure (2). When 
the output became less than 100 cells/sec, the rotorspeed of the centrifuge 
was decreased stepwise as indicated. 
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The 6 cell fractions were collected, centrifugea and resuspended in 3 ml 
PBS. Part of the specimens were used for morphological analysis of May Griin-
wald-Giemsa stained cytocentrifuge slides. The bulk of the cellsuspensions 
were used for FCM-analysis. 
Cell etaining and flow cytomevry (rCM) 
Staining for DNA occurred according to Krishan by adding 0.5 χ 10 cells to 
10 ml hypotonic ethidium bromide (0.1 % trisodium citrate, 25 mg/1 ethidium 
bromide) (3). The relative fluorescence of about 10 cells was measured with 
an ICP-11 pulse cytophotometer (Phywé, FRG) at a flow rate of 400 cells/sec. 
Simultaneous staining for DNA and protein was performed as described re-
cently by Crissman et al (4). Briefly, 1 ml of the cell suspension was fixed 
in 75 % ethanol. After 24 hours 0.2 ml of the fixed cell suspension was added 
to 4 ml PBS containing 13 mM disodium EDTA (PBS-EDTA) and stained with FITC 
and Propidium Iodide (PI). For this purpose FITC was dissolved in absolute 
ethanol (1 mg/ml) of which 0.1 ml was added to 10 ml PBS-EDTA. Of this solu-
tion 0.2 ml was immediately added to the cellsuspension. After approximately 
5 minutes 1 ml of PI (46 mg/ml) was also added to the cell suspension. After 
2-3 minutes 0.2 ml RNA-se (1 mg/ml PBS-EDTA) was added for at least 1-2 minu-
tes prior to FCM-analysis. Stained cells in the reagent solution were analyzed 
in a Phywé ICP-11 pulse cytophotometer, modified for two color analysis. The 
green (< 550 nm) and red (> 590 nm) fluorescence emissions were separated by 
dichromatic filters and measured by separate photomultipliers.'The signals 
were integrated in a multichannel analyzer with display facilities on a mag-
netic tape and further processed by a PDP 11/45 computer. Routinely 50.000 
cells were measured for DNA-content analysis, and 15.000 cells in 2 parameter 
experiments. 
RESULTS 
Plasma cell enriohmenl vith counterflow aentrtfugation (eluiriation) 
Table I shows total cell numbers and plasma cell percentages present in 
bone marrow aspirates and fractions obtained with el-utriation. In most 
cases a substantial increase in the relative plasma cell concentration was 
obtained. 
The mean maximal increment in plasma cell percentages was 3.7 χ the plasma 
cell percentage of the whole bone marrow aspirate (range 1.4 - 14.1 x). The 
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No. Diagnosis 
1 BMG 
2 BMG 
3 MM 
4 MM 
5 BMG 
6 MM 
7 MM 
8 MM 
9 MM 
10 MM 
11 MM 
12 MM 
13 MM 
14 MM 
15 MM 
Bone marrow 
aspirate 
PC % n(106) 
2 98.5 
4 42.1 
6 129.0 
8 108.0 
11 22.0 
12 100.0 
20 61.1 
21 51.4 
21 73.1 
22 101.0 
24 42.7 
28 91.4 
43 35.1 
45 40.0 
67 158.0 
Fraction 1 Fraction 2 Fraction 3 Fraction 4 Fraction 5 Fraction 6 
(2500 rpm) (2250 rpm) (2000 rpm) (1750 rpm) (1500 rpn) (1000 rpm) 
PC t n(106) PC t n(106) PC t n(106) PC t n(106) PC % n(106) PC * n(106) 
0 11.7 1 16.7 2 23.7 2 7.2 2 2.2 3 1.7 
0 12.1 1 4.6 2 7.2 6 5.1 14 2.1 13 0.3 
0 30.8 0 25.2 0 24.2 1 10.5 63 4.2 85 2.8 
0 22.2 0 23.2 2 18.9 17 15.7 24 7.5 63 4.6 
0 3.4 1 3.6 8 2.7 25 5.6 27 1.4 38 0.3 
0 26.6 8 16.5 11 28.6 34 12.9 34 1.4 37 1.1 
0 19.0 8 6.9 22 11.9 58 4.0 62 6.7 40 0.6 
0 16.2 12 15.9 58 7.3 68 2.2 66 0.7 72 0.8 
0 15.5 0 4.7 20 20.0 57 12.7 46 1.8 55 1.4 
0 15.0 3 7.0 8 11.2 12 20.2 71 18.0 76 2.2 
0 12.8 6 3.4 48 8.3 51 4.8 19 1.4 10 0.5 
0 28.4 2 14.3 66 12.1 67 8.6 70 4.3 75 2.4 
0 21.4 10 11.3 32 18.4 72 23.1 81 22.1 68 4.6 
0 8.8 45 1.4 19 4.4 48 8.2 82 7.6 85 5.2 
0 15.0 90 18.0 79 47.2 45 17.2 67 3.8 94 1,7 
Cell recovery 
PC % Total % 
45 64 
49 74 
66 76 
90 85 
89 77 
81 87 
81 80 
80 84 
84 77 
81 73 
68 73 
74 76 
77 75 
88 89 
63 65 
BMG = Benign Monoclonal Gammopathy 
MM = Multiple Myeloma. 
PC% = Plasma Cell Percentage. 
Table I. Plasma cell percentages and absolute cell numbers in different bone marrow fractions obtained 
with counterflow centrifugation 
Fijare 1. Composite of D.'.'A-profiles of unfraotionated bone marrou and Lone 
marrow subpopulations, obtained u¿tk elutriation. 
total cell recovery was 77 + 7.1 % (mean + SD) and the plasma cell recovery 
74.4 + 13.7 %. 
F CM-analisi s of enriched plasma aell fractions 
One parameter DNA-FCM revealed the presence of aneuploidy in the whole bone 
marrow aspirate in 9 out of 12 patients with MM and in none of those with BMG. 
After elutriation, the presence of aneuploidy could be demonstrated in 
two additional patients with MM (patient No. 3 and 4) and in one patient with 
BMG (Patient No. 5) in whom the DNA-profiles of the unfractionated bone marrow 
samples were entirely normal (Figure 1). 
Figure 2 shows the DNA-profiles of the bone marrow (2a) and one of the bone marrow 
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Figure 2. DNA-profiles of unfraationated bone marrow (a) and of a bone marrou 
fraction (Ъ). 
fractions (2b) in a myeloma patient (No. 10). In this patient elutriation un­
masked the presence of a second aneuploid plasma cell population and a large 
number of binucleated cells. In another myeloma patient (No. 15) binucleated 
cells and multinucleated plasma cells were identified (Figure 3), which was 
confirmed by morphological examination of the cytocentrifuge slides. The pre­
sence of multinucleated cells was disclosed with elutriation in 6 out of 12 
myeloma patients. 
In one myeloma patient (No. 14) both aneuploidy and tetraploidy could be 
demonstrated in bone marrow. The tetraploid cells in this patient 
were actively proliferating as was disclosed with elutriation by the demon­
stration of S- and Gp + M-phase cells of this particular cell population 
(Figure 4). 
119 
Bore M a r r c w 
normal binudeaied 
G ? . w Plasma 
-i 1 f— 1 r Η l· 
DNA 
Fracttor 0 ( K ) ) 0 r p m , 
birnjclealrd 
V,A 
нЬ 
f- гас don 5 ( ' 5 0 0 r p m ) 
•nullinucitaled 
о asma ceils 
-» 1— 1 1 1 1 1" —ι 1 1 1— 
enucleateci 
plasma ce Is 
normal 
| G 2 | м - л multmuc eated 
c e M S K \ plasma cells 
-•• • •< 1 t t 1 t Τ > t I 1 -
Figure 3. DNA-profiles of unfractionated bone marrow (a) and two successive 
hone marrow fractions (h and c). 
To demonstrate the multinucleated cells in fraction в the gain set­
ting of the instrument was changed. 
120 
normal 
G, cells 
Gì 
plasma 
«HS 
Λ-
a 
Tetraploid 
plasma cells 
Λ /, V ^ 
Bone Marrcw 
-Τ-^- ì — • ι 
Figure 4. DNA-profites of unfraationated bone marrow (a) and one of the bone 
marrow fractions (h). 
I I I I I I I I I | I I I I I I I I I | I I I I I I I I I [ I I I I I I I I I | I I I I 
'inn 
DNA 
Figure 6. A DNA/protein histogram of normal bone marrow. 
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Figure о. DfJA/vTOteip. histograms of three successive hone marrow fractions 
of a myeloma patient with hypodiploid plasma cells, 
(the one parameter DiJA-histogram is shown in figure 6-a3 as well), 
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Two parameter DNA/protein-FCM of normal bone marrow cells (Figure 5) re­
vealed a progressive increase in protein content of cells during the cell 
cycle, with an average protein content of cells in G2 + M-phase nearly twice 
as much as the average of Gj-cells In case of bone marrow plasmocytosis, the 
relative high protein content of plasma cells makes them easily to be discer­
ned on a two parameter DNA/protein plot. 
Figure б (a-c) shows the DNA/protein histograms of three successive cell 
fractions, obtained with counterflow centrifugation of a bone marrow sample 
from a myeloma patient (No. 13). Evidently the average protein content of the 
plasma cells increased at each successive elutriation step, which corresponds 
to the increase in average cell size. Moreover, these plots demonstrate, that 
two parameter FCM analysis disclosed two additional important plasma cell 
characteristics in this particular patient. First, the UNA-content of the 
plasma cells seems less than the DNA-content of the normal G,-cells (hypodi-
ploid), which was not apparent from the one parameter DNA-profiles (see 
Figure 6a box). Secondly, even after plasma cell enrichment, which usually is 
associated with the enrichment of S- and G ? + M-phase cells, no transition 
of plasma cells into S-phase could be demonstrated, indicating a low prolife­
ration activity of these cells in this particular patient. In another myeloma 
patient however(No 12) DNA/protein-FCM of one of the fractions disclosed 
transitions of both diploid (normal) and hypodiploid cells (plasma cells with 
high average protein content) to the S- and G ? + M-phase Moreover, the tetra-
ploid plasma cells even show a further increase in protein and DNA content 
suggesting ongoing proliferation of tetraploid plasma cells as well (Figure 7). 
DISCUSSION 
FCM analysis of elutriated bone marrow cell fractions enabled the detec­
tion of aneuploid cells in two patients with MM and one patient with BMG, in 
whom the DNA-profiles of the unfractionated bone marrow aspirates were enti­
rely normal. A second aneuploid peak was disclosed, and a proliferating tetra­
ploid plasma cell clone could be demonstrated after elutriation in two addi­
tional myeloma patients, whereas in other patients multinucleated cells could 
be shown. 
Two parameter DNA/protein-FCM disclosed the existence of small degree 
hypodiploid plasma cells and provides means to analyze the cell kinetic pro­
files of plasma cells in heterogeneous cell fractions. 
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Figure 7. D'/A/pvotein histogram of one of the bone marrow fractions of 
myeloma patient. 
Elutriation has the advantage over other cell-fractionating methods, 
to result in a high cell-recovery with intact cell-viability, 
whereas the simultaneous separation of multiple cell-types makes this method 
especially suitable for human bone marrow (4,5). In the present study, 
elutriation was accomplished by a б-steps decrease of the centrifuge rotor 
speed, which resulted in a substantial enrichment of plasma cells in 
the majority of patients. 
Latreille et al have reported a 65 2 incidence of aneuploidy in myeloma 
patients (7). The results of the present study indicate, that the incidence 
of aneuploidy in MM might in fact be higher when plasma cell enriched 
fractions are studied. Of particular interest in this regard is the finding 
of aneuploid cells in a patient with BMG. As the presence of aneuploid cells 
is supposed to be indicative for malignant disease (8), the demonstration of 
these cells might indicate in fact the existence of a malignant gammopathy 
in this particular patient. In general, this finding suggest the potential 
of this method to differentiate between benign and malignant monoclonal 
gammopathies. 
As shown, elutriation combined with FCM enables the study of plasma cell 
proliferation kinetics. Especially when cells are stained simultaneously 
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for DNA and protein, plasma cells can be distinguished from other bone marrow 
elements, which allows the simultaneous measurement of proliferation charac-
teristics of plasma cells and other hematopoietic cells. The clinical rele-
vance of such measurements is indicated by recent studies in which a correla-
tion was demonstrated between disease progression and the proliferative acti-
vity of plasma cells (9,10). Moreover, such measurements may be valuable in 
monitoring the effects of treatment. 
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ABSTRACT 
Counterflow centrifugation (elutriation) was used to separate an exponen-
tially growing lymphoblastic cell line (RPMI 1788) in subpopulations, enriched 
with cells in a distinct phase of the cell cycle. The subpopulations were sub-
sequently recultured for 18 hours, during which the proliferation kinetics was 
monitored with DNA-flow cytometry (FCM), two parameter DNA/RNA-FCM, H-thymi-
dine incorporation and cell counting. 
Analysis of the flow cytometric data was performed by plotting the sequen-
tial changes in specific cell cycle compartments of the histograms. 
The results indicate that counterflow centrifugation provides means to ob-
tain unpertubred sunchronized subpopulations of cells in different phases of 
the cell cycle. Flow cytometric analysis of such cell-cohorts, during recul-
turing, permits the estimation of cell cycle phase durations. 
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INTRODUCTION 
Counterflow centnfugation (elutnation) of cell susoensions, render 
cell populations, different in cell size (1). Because, during cell-cvcle 
traverse, cells gradually increase in size and mass up to mitosis (2), elutna-
tion provides means to obtain cell populations enriched with cells in various 
phases of the cell-cycle. Recultunng of these fractions subsequently results 
in cellkinetic profiles, similar to synchronized cell copulations obtained with 
stathmokmetic agents or metabolic manipulations (5). 
The present study was designed to determine the feasibility of combined 
counterflow centnfugation and flow cytometry (FCM) for the analysis of the 
cell cycle. 
MATERIALS AND METHODS 
Cello 
A human lymphoblastic cell line (RPMI 1788) was maintained in RPMI-1640 
containing 2 mM glutamine, 50 lU/ml penicillin, 50 ug/ml streptomycin and 10 % 
(v/v) fetal calf serum. Cells were studied during the exponential growth phase 
at a temperature of 370C in humidified air with 5 % carbon dioxide. 
Counterflow centnfugatbon (elutviation) 
For elutnation a Beckmann J2-21C centrifuge and JE-6 elutriator rotor was 
employed. 
The rotor, separation chamber and connecting tubes were sterilized before 
cells were injected,by pumping 70 % ethanol through the apparatus during 30 
minutes. Ethanol was removed by flushing the apparatus with 50 ml of sterile, 
phosphate buffered saline (PBS). Then PBS was replaced by growth medium 
(RPMI-1640) containing 10 % fetal calf serum before the addition of cells. 
о 
Ten ml of the cell suspension (10 cells/ml) was injected slowly (0.3 ml/mm) 
into the connecting tubes and subsequently pumped at 5 ml/min into the elu­
tnation rotor. Elutnation was carried out at 37 С and initiated at a rotor-
speed of 2200 rpm and at a flow rate of 9 ml/mm. The procedure was accom­
plished by stepwise decrease of the rotorspeed. Cells in the effluent tube 
were monitored by an electro optical scatter unit (Techmcon), allowing con­
trol of cell number and cell size during the elutnation procedure (6). The 
rotorspeed was decreased when the cell output became less than 100 cells/sec. 
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Six fractions were obtained, which were centrifuged and resuspended to a cell 
о 
concentration of about 1 5 χ 10 cells/ml Approximately 90 minutes were re­
quired to collect the fractionated cells from the elutnator rotor 
RecuttuPbng 
The six fractions were diluted m RPMI to 10 cells/ml and each fraction 
distributed, over 25-30 tissue culture dishes (3 nl/dish) Culture conditions 
were identical to those of the unfractionated cells Cytokmetic parameters 
of the recultured fractions were monitored over a 18-hour period by analysis 
of the cellular content of one culture dish of each fraction after various 
3 
time intervals with Η-thymidine incorporation, DNA-FCM, two parameter DNA/ 
RNA-FCM and cell counting. 
Н-ікутгагпе inaorporation 
Aliquots of 1 ml eelIsuspension at half hourly or hourly intervals were 
3 
incubated with 2 yCi Η-thymidine (Radiochemical Centre Amersham specific 
activity 5 Ci/mmol) for 60 minutes at 37 С H-thymidme uptake was arrested 
by adding 2 ml cold-medium (0C) with an excess of unlabeled thymidine. The 
cells were collected on glass fibre filters (Schleicher and Schuil No 9), 
washed with water and precipitated with IM perchloric acid The total amount 
of radioactivity in the perchloric acid precipitable fraction was counted in 
a liquid scintillation counter (LKB 81000). 
Cell зіагпгпд and fluorescence measurement 
Staining for DNA was performed by adding 0.5 χ 10 cells to 5 ml hypotonic 
ethidium bromide (0 1 % trisodium citrate, 25 mg ethodium bromide), supple­
mented with 0 2 ml of 0 05 % Nomdet-P40 (7,8) The relative fluorescence of 
5 
10 cells was measured with an ICP-11 pulsecytophotometer (Phywé, Gottingen, 
Germany) at a flow rate of 400 cells/sec. 
Simultaneous staining for DNA and RNA was performed according to Tráganos 
and Darzynkiewicz (9) The cell suspension (0 2 ml) was mixed with 0.4 ml of 
a solution containing 0.1 % (v/v) Triton X-100, 0.08 N HCl and 0 15 M NaCl. 
After 30 sec 1.2 ml Acridme Oranqe (15 yg/nl in 10"3 M EDTA, 0.15 M NaCl, 
0.1 M phosphate-citrate buffer pH 6 0) was added resulting in a final dye 
-5 
concentration of 2 1 χ 10 M Acridine Orange Stained cells in the reagent so­
lution were analyzed in an ICP-11 modified for two parameter analysis The 
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green fluorecence (DNA) and red fluorescence (RNA) emissions were separated 
optically by a dichroic mirror and measured by separate photomultipliers. The 
electric signals were accumulated in dual parameter displays and stored on a 
magnetic tape for computer analysis and copying (PDP 11/45). The data from 
4 
each DNA/RNA histogram are based on the analysis of 1.5 χ 10 cells per sample. 
Histogram analysis 
Analysis of time sequences of DNA and DNA/RNA histograms was performed by 
selecting certain "windows" of DNA or RNA content and plotting as a function 
of time the relative cell numbers present in these compartments (FP.-analysis 
according to Zietz 10). 
In DNA histograms with the G,- and G ? + M-peak respectively in channel 31 and 
62, cells in early S-phase were assumed to be in channel 38-43, and cells 
late in S-phase in channel 50-55 (Figure 1). Traverse of cells from the early 
to late S-phase compartment (12 channels) was estimated to take about 0.4 
part of the total S-phase time (30 channels). 
In two parameters DNA/RNA histograms a distinction was made between G, 
cells with low RNA (G. A) and G, cells with higher RNA-content (G, B), accor­
ding to a line drawn at a minimal RNA-content of S-phase cells (Figure 2)(11). 
The percentages of cells in these two compartments at various time intervals 
during reculturing were plotted, showing the time evolution of changes in 
these compartments (FP. analysis). 
Estimation of percentages of cells in Gp + M- and S-phase in synchronous 
growing cell populations was performed according to Barlogie et al (12). 
RESULTS 
A distribution profile of DNA and RNA values in individual cells from the 
exponentially growing cell culture is shown in Figure 2. The intensity of 
the green fluorescence is proportional to the DNA-content per cell and per­
mits to subclassify the cells into G,, S and G- + M-phase cells. The DNA-pro-
files obtained with this two parameter method are identical to those, obtained 
by the one parameter DNA-staining with ethidium bromide. Analysis of the red 
fluorescence pattern indicates a progressive increase in RNA during the cell 
cycle, so that average G 2 + M cells have nearly twice as much RNA as average 
G, cells. The heterogeneity of G, cells with recpect to their RNA-content, 
together with the high RNA-content of S-phase cells, suggest that only cells 
with RNA-values above the marked threshold are entering the S-phase directly 
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Figure 1. DM-ppofile of an exponentially growing lymphoblactia oell-line (ИРШ 
1788). An early S-phase and a late S-phase aomvariment were located 
respectively in channel 28-43 and channel 5(7-65 of minimal distance 
of G,- respectively G„ + M-peak of two times the standard deviation 
of u , and G„ + M fluorecenae intensity. 
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Figure 2. DliA-RUA histogram of an exponentially growing lymphoblastic cell-Vine 
(RPMI 1788). G1 cells with low RNA content (йЛ cells) were dis­
tinguished from G, cells with high RNA content (G.B cells) according 
to a line drawn at minimal RUA content o^ S-phase cells. 
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(figure 2). G, cells with low RNA content (G, A cells) apparently first in­
crease their RNA-content during G, phase before entering the S-phase. 
Fraction 1 
2 
3 
4 
5 
6 
v · 
60 7 
34 0 
16 8 
8.1 
11 6 
18 В 
OjB 
зг 
43 
50 
40 
27 
28 
-, 
6 
9 
4 
1 
1 
0 
s % 
6 0 
14 8 
25 0 
39 9 
36 3 
26 9 
G 2M \ 
0.8 
2 3 
7 8 
11 9 
25 0 
26 3 
Table 1. Percentages of cells in distinct cell cycle phases as measured witk 
FCM in six subpopulations obtained by elutriation of an exponential­
ly growing lymphoblastic cell-line (RPMI 1788). 
Table 1 shows the percentage of cells in the various cell-cycle phases in 
the six fractions with elutriation of the RPMI 1788 cell-line. G 1 A cells are 
maximally enriched in fraction I; G, В cells in fraction 2 and 3; S-phase 
cells in fraction 4 and 5, and G- + M-phase cells in fraction 5 and 6. 
Reculturing of these six fractions show sequential changes in the various cell 
cycle windows, as depicted in figure 3. 
Fraction l shows that an initial decrease of G, В cells parallels an in­
crease in early S, followed by a decrease in G, A, which is caused 
probably by a continuous flow of cells from G, A to G, В and S-phase. The frac­
tion of cells in late S-phase steadily increases to a maximum value at about 
13 hours. The FP. curves of fraction 2 are essentially similar to those of 
ι •
 J 
fraction 1, although they show a phase shift of about 3 hours to the left i.e. 
the maximum value in late S-phase is reached after about 10 hours, fraction 3 
shows accumulation of cells in early S-phase after two hours and in late 
S-phase after 6 hours, indicating a traverse of cells from early S-phase to 
late S-phase in 4 hours. Assuming a constant DNA-synthesis rate, the S-phase 
might be estimated to be about 10 hours minimally (4:0.4 = 10 hours). The FPi 
curves of fraction 4 show, that the maximum percentage of cells in late 
S-phase is reached already after 5 hours.Oscillations of the relative cell-
numbers in early and late S-phase in this figure suggest a total cycle time 
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2 4 6 θ 10 12 14 16 18 
hours 
2 4 6 8 10 12 14 16 18 
hours 
figure 3. FP- -curves (fraction of population in conpartment г) of six syn­
chronized subpopulations of RPMI 1788 cells (see text). 
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of about 18 hours. The FP. curves of fraction 5 permis to estimate the dura­
t ion of c e l l cycle traverse from G1 A to G, В respectively G-, В to early 
S-phase. Both time periods are about 4 hours, whereas the time duration of the 
late S-phase to the peak value in the G, A compartment suggest a G2 + M-phase 
duration of about 3.0 hours. Ihe FP^  curves of fraation 6 are essent ial ly s i ­
milar to those obtained in f ract ion 5. The sum of the cycle phase durations 
( i . e . G1 A, S and G« + M-phase is about 17 hours and corresponds with the es­
timated cel l cycle time in f ract ion 4. In table 2 the estimated cel l cycle 
phase durations are summarized. 
S-phase 
G2+M-phase 
G-jA t o GiB 
C e l l c y c l e t i m e 
= + 10.0 hours 
= + 3.0 hours 
= + 4.0 hours 
= + 18.0 hours 
Table 2. Estimated cell ayate -phase durations of an exponenzially growing 
lymphoblastic cell-line (BVMI 1788). 
H - T h y m i d n e ^ c o r p o r a t i o n — . Cell number 
d p m / 1 0 4 cells χ 10 6 
3 0 0 -
2 0 0 
1 0 0 
FRACTION 3 
12 18 
hours 
12 18 
hours 
Figure 4. Η-thymidine incorporation and aellnumbcrs durimi reculturing of 
fractions 3 and S. 
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In f igure 4 the results are shown of the H-thymidme incorporation in 
3 
fract ions 3 and 5 during recul tur ing. Osci l lat ions in the Η-thymidine uptake 
is accordant with estimation of the ce l l cycle time as determined with DNA-FCM. 
The doubling time of the cellnumber in these two fract ions is about 18 hours 
as w e l l . 
DISCUSSION 
Cell synchronization with counterflow centri fugati on offers the advantage, 
that one obtains with a simple procedure cell populations, which in one time 
are partially synchronized at different phases of the cell cycle. This effect 
is attained without use of metabolic inhibitors, temperature changes, nutrient 
deprivation and without removing cells from their culturing conditions (5). 
Reculturing of the fractions combined with FCM, subsequently disclose the 
traverse of cells through the cell cycle and allow with FP. analysis of the 
histograms to estimate the various cell cycle phase durations. As shown, the 
cell kinetic data, obtained in the various fractions are in some way comple­
mentary, which permits to unravel the composition of the entire cell cycle. 
3 
Results obtained with Η-thymidine uptake were shown to correlate well with 
FCM-data. 
The estimated cell cycle phase durations in this preliminary study must be 
considered inaccurate yet, as the fractions obtained with elutriation were 
only partially synchronized in order to obtain an adequate cellnumber in each 
fraction. Moreover, the assumption of a constant DNA synthesis rate for cal­
culation of the S-phase duration is perhaps not correct (13,14). On the other 
hand cell traverse from the G. A to the G, В compartment prior to entering 
the S-phase, as demonstrated by Darzynkiewicz et al (10), was confirmed by 
the FP. curves obtained in fraction 5 and 6, showing accumulation of cells 
successively in G, A, G, В and early S-phase. 
Elutriation combined with FCM, at least seems a promising method for cell 
cycle analysis, especially with regard to the determination of the duration 
of cell cycle phases. Consequently, it may be expected, that the application 
of this method will contribute to the understanding of the effects of chemo-
therapeutic drugs on the various cell cycle phases (15). 
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SUMMARY 
141 
In chapter I a short review is presented of the development of flow cyto-
metry as applied in clinical hematology, whereas also the objective of the 
study is outlined in this chapter. 
In Chapter II some fundamental concepts of cellkinetics are described. 
Moreover, some cell kinetic data of normal and leukemic bone marrow in man 
are summarized. 
In Chapter III the applied flow cytometric procedures are outlined. The 
instruments, the measuring procedure, the methods for histogram analysis and 
the cell staining methods are successively described. 
In Chapter IV a method is described allowing the quantification of peri-
pheral nucleated cell admixture in bone marrow aspirates. The method is based 
51 125 
on the observation(with Cr-labeled erythrocytes and I-labeled albumin) 
that nearly all erythrocytes (or hemoglobin) in bone marrow aspirates are 
derived from peripheral blood. 
In Chapter V the size and the prognostic significance of the S-phase com-
partment in bone marrow (% S, ) in adult patients with acute leukemia is 
reported. The median % S. in 31 patients with acute non-lymphocytic leukemia 
(ANLL) at diagnosis and in 14 patients with ANLL at relapse did not differ 
significantly from the median % S. in normal bone marrow. On the other hand 
in 12 out of 23 patients with acute lymphocytic leukemia (ALL) at diagnosis 
and in 6 out of 11 patients with ALL at relapse, the % S. was much increased 
compared to normal. 
Patients with ALL at diagnosis in whom the t S. was high appeared to have 
a bad prognosis with regard to remission duration and survival, compared with 
those having a normal or low % S. . 
In Chapter VI the size of the S-phase compartment in blood (% S . ) and 
bone marrow [% S. ) is reported as measured in patients with chronic myeloge-
nous leukemia (CML) at different disease stages. 
At diagnosis and at "remission" the % S, in these patients appeared to be of 
the same order of magnitude as in normal bone marrow. However, at malignant 
metamorphosis the % S. appeared higher than normal in 3 out of 4 
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patients in whom this percentage could be determined reliably Aneuploidy was 
demonstrated in 4 out of 11 patients with CML at this disease stage. 
Peripheral nucleated cell admixture in bone marrow aspirates was shown to be 
considerable, especially in CML patients with a high white blood cell count 
(> 100 χ 10 9/1). 
In Chapter vji changes in % S. after intravenous push injections of Ara-C 
in 11 patients with ANLL are described. DNA-flow cytometry revealed a slight 
decrease of the " S. at 7 hours after the injection but showed subsequently 
an increase to a maximum value exceeding the pretreatment value at about 
30 hours after the Ara-C injection 
3 
Labeling Indices (determined with Η-thymidine autoradiography) reached, after 
an initial decrease, pretreatment levels at about 24 hours after injection. 
3 
Η-thymidine incorporation increased after an initial inhibition to about 
twice the pretreatment levels at 30-40 hours after injection. 
The perturbation of the cell cycle appeared identical with the three dif-
2 2 2 
ferent Ara-C dosages used (i.e. 100 mg/m , 380 mg/m and 1000 mg/m ). 
The observations suggest that with regard to the cell kinetics,24-hour 
scheduling might be optimal for Ara-C given by push-injections 
In Cnavter Vili a simplified method is described for simultaneous DNA and 
protein staining of human hematopoietic cells, with propidium iodide (PI) 
and fluorescein isothiocyanate (FITC) 
In contrast to previous protocols, all reagents are added sequentially 
to ethanol fixed cells through which no centrifugation steps are required, 
and cell clumping is prevented. The staining time is reduced to 10 minutes 
as compared to 3 hrs by previous methods. 
In Chapier IX it is shown, that plasma cell enrichment with counterflow 
centnfugation of bone marrow in patients with multiple myeloma or benign 
monoclonal gammopathy, augments the discriminatory potential of flow cyto­
metry with regard to cell kinetic profiles and ploidy abnormalities of plasma 
cells. 
In Cnapter X is demonstrated that with counterflow centnfugation of cul­
tured cells, subpopulations are obtained enriched with cells at well defined 
cell cycle phases. Recultunng of these synchronized fractions enabled flow 
cytometric analysis of various cell cycle phase durations. 
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SAMENVATTING 
145 
In Hoofdstuk I wordt een beknopt overzicht gegeven van de ontwikkeling 
van flow cytometrie binnen de klinische hematologie terwijl tevens in dit 
hoofdstuk het doel van het onderzoek wordt uiteengezet. 
In Hoofdstuk IJ worden enkele basis begrippen van de celkinetiek besproken 
en wordt een overzicht gegeven van de celkinetische gegevens betreffende het 
normale en leukemische beenmerg bij de mens. 
In Hoofds Luk III worden de in dit onderzoek gebruikte flow cytometrische 
methoden uiteengezet. De apparatuur, de feitelijke meetprocedure, de methoden 
voor de analyse van de verkregen histogrammen en de cel kleuringsmethoden wor-
den achtereenvolgens beschreven. 
In Hoofdstuk IV wordt een methode beschreven welke de mogelijkheid biedt 
de mate van bijmenging van perifere kernhoudende cellen in beenmergaspiraten 
te kwantificeren. Deze methode berust op de waarneming (verricht met Cr -
125 gelabelde erythrocyten en I -gelabeld albumine) dat nagenoeg alle erythro-
cyten (of hemoglobine) in een beenmergaspiraat afkomstig zijn van het peri-
fere bloed. 
In Hoofdstuk V wordt verslag gedaan van een onderzoek naar de grootte, én 
de prognostische betekenis van het S-fase compartiment in het beenmerg 
(% S. ) bij volwassen patiënten met akute leukemie. 
Het mediane % S. by 31 patiënten met akute niet lymfatische leukemie 
(ANLL) ten tijde van de diagnose en bij 14 patiënten met ANLL ten tijde 
van het recidief verschilde niet significant van het mediane % S. zoals dat 
werd gevonden in het beenmerg van gezonde kontrol e personen. Daarentegen 
werd bij 12 van de 23 patiënten met akute lymfatische leukemie (ALL) bij 
diagnose, en bij 6 van de 11 patiënten met ALL tijdens het recidief een 
beduidend hoger % S. gemeten dan normaal. 
Patienten met ALL met een hoog % S. bleken een significant slechtere prog-
nose te hebben wat betreft remissieduur en overleving, dan patiënten met 
een normaal of laag % S. . 
In Hoofdstuk VI wordt het onderzoek beschreven naar de grootte van het 
S-fase compartiment in bloed (% S . ) en beenmerg (% S. ) van patiënten 
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met chronische myeloide leukemie (CML), in verschillende stadia van de ziekte. 
Ten tijde van diagnose en bij "remissie" bleek het % S. niet significant te 
verschillen van normalen. 
Tijdens "maligne metamorfose" echter, bleek het % S. significant hoger dan 
normaal althans bij 3 van de slechts 4 patiënten waarbij dit percentage be-
trouwbaar kon worden bepaald. Aneuploidie kon worden aangetoond bij 4 van de 
11 patiënten met CML in deze ziekte-fase. 
üijmenging van perifere kernhoudende cellen in beenmergaspiraten bleek 
vaak aanzienlijk te zijn bij CML patiënten met een hoog perifeer leukocyten 
aantal (> 100 χ 10 9/1). 
In HoofdsLuk VII worden de veranderingen gerapporteerd in het percentage 
S-fase cellen van het beenmerg [% S. ) na een intraveneuze bolus injectie 
van Ara-C. 
Met DNA-flow cytometrie werd 7 uur na de injectie een geringe daling van 
het % S, gemeten, terwijl vervolgens dit percentage steeg tot een maximale 
waarde die ongeveer 30 uur na injectie het uitgangsniveau overschreed. 
3 
De labeling indices (gemeten met Η-thymidine autoradiografie) bereikten, 
na een initiële daling, ongeveer 24 uur na injectie het uitgangsniveau. 
3 
Η-thymidine incorporatie tenslotte, steeg 30-40 uur na Ara-C injectie 
(na een aanvankelijke remming) tot een waarde van ongeveer twee maal het 
uitgangsniveau. 
De celcyclus veranderingen zoals die ontstonden na toediening van drie 
2 2 2 
verschillende doses Ara-C (te weten 100 mg/m , 380 mg/m en 1000 mg/m ) bleken 
identiek. 
De resultaten suggereren dat celkinetisch, éénmalige toediening van Ara-C 
per etmaal, althans bij intraveneuze bolus injecties van dit cytostaticum, 
de aangewezen methode is. 
In Hoofdstuk Vili wordt een vereenvoudigde methode beschreven voor de ge-
lijktijdige kleuring van menselijke hematopoietische cellen op DNA en eiwit. 
Hierbij wordt gebruik gemaakt van de fluorochromen propidium iodide (PI) en 
fluoresceine isothiocyanaat (FITC). 
In tegenstelling tot eerder beschreven kleuringsmethoden worden bij deze 
methode achtereenvolgens alle reagentia toegevoegd aan met alkohol gefixeer-
de cellen, waardoor tussentijds centrifugeren niet langer noodzakelijk is en 
celklontering wordt vermeden. 
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De beschreven kleuringsmethode is tevens aanmerkelijk korter dan eerder be-
schreven methoden (10 minuten i.p.v. + 3 uur). 
In liocfdsiuk TX wordt aangetoond dat tegenstroom centrifugatie (of cel 
elutriatie) een geschikte methode is om bij patiënten met multipel myeloom 
(MM) of benigne monoclonal gammopathie (BMG) beenmerg fracties te verkrijgen 
die verrijkt zijn met plasma cellen. 
Flow cytometrisch onderzoek (DNA-flow cytometrie of DNA/eiwit-flow cytome-
trie) van deze met plasma cellen verrijkte fracties verschaft meer informatie 
dan flow cytometrisch onderzoek van het totale (niet gescheiden) beenmerg. 
Dit betreft vooral gegevens betreffende enkele cel kinetische parameters, en 
afwijkingen in het DNA-gehalte van plasma cellen. 
In Iwofdm.ik X wordt aangetoond dat d.m.v. tegenstroom centrifugatie (of 
cel elutriatie) van cellen in kweek, fracties kunnen worden verkregen, ver-
rijkt met cellen die verkeren in een bepaalde fase van de celcyclus. Door 
deze gesynchroniseerde celpopulaties opnieuw in kweek te brengen wordt de 
mogelijkheid geschapen met behulp van flow cytometrie onderzoek te doen naar 
de tijdsduur van de onderscheiden celcyclus-fasen. 
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S T E L L I N G E N 
1 
Kwantitatieve gegevens omtrent cel ei genschappen in beenmergaspiraten hebben 
alleen waarde indien hierin de mate van bijmenging met perifere kernhoudende 
cellen gemeten is. 
dit proefschrift 
2 
Het percentage cellen in S-fase van het beenmerg bij acute niet-lymfatische 
leukaemie verschilt niet wezenlijk van dat in normaal beenmerg. 
dit proefschrift 
3 
Een hoog percentage cellen in S-fase van het beenmerg bij acute lymfatische 
leukaemie heeft een zeer slechte prognostische betekenis. 
dit proefschrift 
4 
Het DNA-gehalte van plasma cellen bij het multipel myeloom is meestal in 
belangrijke mate afwijkend van normaal. 
dit proefschrift 
5 
De verlaagde "Labeling Index" van leukaemische Ыasten kan men beschouwen 
als uiting van een gestoorde differentiatie. 
6 
Bij het ontstaan van Thrombotische Thrombocytopenische Purpura spelen proges­
tative en oestrogenen een belangrijke rol. 
eigen waarneming 
7 
De gelijkenis van Thrombotische Thronibocytopenische Purpura en (pre)eclampsie 
is soms zo treffend, dat een gemeenschappelijke Pathogenese waarschijnlijk 
moet worden geacht. 
θ 
Indien bij patiënten met multipel myeloom een stabiele remissie is verkregen 
lijkt continuering van chemotherapie niet zinvol. 
Al exam'an R., Gehan E., Haut Α., Saiki J., 
Weick J. Blood 51, 1005, 197Θ 
Durie BGM., Russell DH., Salmon SE. 
Lancet II: 65, 1980 
9 
De opvatting, dat tijdens hypoglycaemie bij insuline-afhankelijke diabeten 
een zodanige stimulering van de secretie van contraregulerende hormonen 
optreedt, dat hierdoor een hyperglycaemie ontstaat (het zogenaamde Somogyi 
effect), is onjuist. 
Gale EAM., Kurtz AB., Tattersall RB. 
Lancet II: 279, 1980 
10 
Bij een afsluiting van de arteriae iliaca externa en femoral i s conmunis 
dient de half-gesloten thromboëndarteriëctomie met behulp van de gemodi-
ficeerde ringstripper als reconstructieve ingreep overwogen te worden. 
Donders, H.P.C., v. Dongen RJAM 
VASA 8, 343, 1979 
11 
De mening, dat "Jogging" bescherming biedt tegen het krijgen van hart-
vaatziekten, berust niet op overtuigende feiten. 
Rennie D., Hollenberg NK. 
N. Engl. J. Med. 301, 103, 1979 
12 
Bij, door het parlement voorgestelde wijzigingen van departementale 
begrotingen dient het totaal kader van de Miljoenennota opnieuw ter dis-
cussie te staan. 
Le Blanc LJCM NRC-Handelsblad 18-7-1981. 
13 
Hollanditis is geen "Veteranen-ziekte". 
R.S.G. Holdrinet Nijmegen, 2 October 1981 



